<?xml version="1.0" encoding="UTF-8"?>
<OAI-PMH xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd">
  <responseDate>2024-05-03T02:41:11Z</responseDate>
  <request verb="GetRecord" identifier="oai:pubmedcentral.nih.gov:8961707" metadataPrefix="pmc">https:/www.ncbi.nlm.nih.gov/pmc/oai/oai.cgi</request>
  <GetRecord>
    <record>
      <header>
        <identifier>oai:pubmedcentral.nih.gov:8961707</identifier>
        <datestamp>2022-03-31</datestamp>
        <setSpec>yjbm</setSpec>
        <setSpec>pmc-open</setSpec>
      </header>
      <metadata>
        <article xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xsi:schemaLocation="https://jats.nlm.nih.gov/ns/archiving/1.3/ https://jats.nlm.nih.gov/archiving/1.3/xsd/JATS-archivearticle1-3.xsd" dtd-version="1.3" xml:lang="en" article-type="research-article">
          <processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats">
            <restricted-by>pmc</restricted-by>
          </processing-meta>
          <front>
            <journal-meta>
              <journal-id journal-id-type="nlm-ta">Yale J Biol Med</journal-id>
              <journal-id journal-id-type="iso-abbrev">Yale J Biol Med</journal-id>
              <journal-id journal-id-type="publisher-id">YJBM</journal-id>
              <journal-title-group>
                <journal-title>The Yale Journal of Biology and Medicine</journal-title>
              </journal-title-group>
              <issn pub-type="ppub">0044-0086</issn>
              <issn pub-type="epub">1551-4056</issn>
              <publisher>
                <publisher-name>YJBM</publisher-name>
              </publisher>
            </journal-meta>
            <article-meta>
              <article-id pub-id-type="accession">PMC8961707</article-id>
              <article-id pub-id-type="pmcid">PMC8961707</article-id>
              <article-id pub-id-type="pmc-uid">8961707</article-id>
              <article-id pub-id-type="pmid">35370486</article-id>
              <article-id pub-id-type="publisher-id">yjbm95145</article-id>
              <article-categories>
                <subj-group subj-group-type="heading">
                  <subject>Original Contribution</subject>
                </subj-group>
                <series-title>Focus: The Science of Stress</series-title>
              </article-categories>
              <title-group>
                <article-title>Rap1A, Rap1B, and β-Adrenergic Signaling in Autologous HCT: A
Randomized Controlled Trial of Propranolol</article-title>
              </title-group>
              <contrib-group>
                <contrib contrib-type="author">
                  <name>
                    <surname>Johnson</surname>
                    <given-names>Alexander K.</given-names>
                  </name>
                  <xref rid="A1" ref-type="aff">a</xref>
                  <xref rid="COR1" ref-type="corresp">*</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Lorimer</surname>
                    <given-names>Ellen L.</given-names>
                  </name>
                  <xref rid="A2" ref-type="aff">b</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Szabo</surname>
                    <given-names>Aniko</given-names>
                  </name>
                  <xref rid="A3" ref-type="aff">c</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Wu</surname>
                    <given-names>Ruizhe</given-names>
                  </name>
                  <xref rid="A3" ref-type="aff">c</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Shah</surname>
                    <given-names>Nirav N.</given-names>
                  </name>
                  <xref rid="A4" ref-type="aff">d</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>D’Souza</surname>
                    <given-names>Anita</given-names>
                  </name>
                  <xref rid="A4" ref-type="aff">d</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Chhabra</surname>
                    <given-names>Saurabh</given-names>
                  </name>
                  <xref rid="A4" ref-type="aff">d</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Hamadani</surname>
                    <given-names>Mehdi</given-names>
                  </name>
                  <xref rid="A5" ref-type="aff">e</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Dhakal</surname>
                    <given-names>Binod</given-names>
                  </name>
                  <xref rid="A5" ref-type="aff">e</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Hari</surname>
                    <given-names>Parameswaran</given-names>
                  </name>
                  <xref rid="A5" ref-type="aff">e</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Rao</surname>
                    <given-names>Sridhar</given-names>
                  </name>
                  <xref rid="A6" ref-type="aff">f</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Carlson</surname>
                    <given-names>Karen</given-names>
                  </name>
                  <xref rid="A4" ref-type="aff">d</xref>
                  <xref rid="A6" ref-type="aff">f</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Williams</surname>
                    <given-names>Carol L.</given-names>
                  </name>
                  <xref rid="A2" ref-type="aff">b</xref>
                  <xref rid="EQ1" ref-type="author-notes">1</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Knight</surname>
                    <given-names>Jennifer M.</given-names>
                  </name>
                  <xref rid="A1" ref-type="aff">a</xref>
                  <xref rid="A7" ref-type="aff">g</xref>
                  <xref rid="EQ1" ref-type="author-notes">1</xref>
                </contrib>
                <aff id="A1"><label>a</label>Department of Psychiatry, Medical College of Wisconsin,
Milwaukee, WI, USA</aff>
                <aff id="A2"><label>b</label>Department of Pharmacology and Toxicology, Medical
College of Wisconsin, Milwaukee, WI, USA</aff>
                <aff id="A3"><label>c</label>Institute for Health &amp; Equity, Division of
Biostatistics, Medical College of Wisconsin, Milwaukee, WI, USA</aff>
                <aff id="A4"><label>d</label>Division of Hematology and Oncology, Department of
Medicine, Medical College of Wisconsin, Milwaukee, WI, USA</aff>
                <aff id="A5"><label>e</label>Division of BMT and Cellular Therapy, Department of
Medicine, Medical College of Wisconsin, Milwaukee, WI, USA</aff>
                <aff id="A6"><label>f</label>Blood Research Institute, Versiti, Milwaukee, WI,
USA</aff>
                <aff id="A7"><label>g</label>Departments of Medicine and Microbiology &amp;
Immunology, Medical College of Wisconsin, Milwaukee, WI, USA</aff>
              </contrib-group>
              <author-notes>
                <corresp id="COR1"><label>*</label>To whom all correspondence should be addressed:
Alexander K. Johnson, MD, Department of Psychiatry, Medical College of
Wisconsin, Milwaukee, WI; Email: <email>aljohnson@mcw.edu</email>.</corresp>
                <fn fn-type="equal" id="EQ1">
                  <label>1</label>
                  <p>Co-senior authors</p>
                </fn>
              </author-notes>
              <pub-date pub-type="epub">
                <day>31</day>
                <month>3</month>
                <year>2022</year>
              </pub-date>
              <pub-date pub-type="collection">
                <month>3</month>
                <year>2022</year>
              </pub-date>
              <volume>95</volume>
              <issue>1</issue>
              <fpage>45</fpage>
              <lpage>56</lpage>
              <permissions>
                <copyright-statement>Copyright ©2022, Yale Journal of Biology and
Medicine</copyright-statement>
                <copyright-year>2022</copyright-year>
                <copyright-holder>Yale Journal of Biology and Medicine</copyright-holder>
                <license>
                  <ali:license_ref specific-use="textmining" content-type="ccbynclicense">https://creativecommons.org/licenses/by-nc/4.0/</ali:license_ref>
                  <license-p>This is an open access article distributed under the terms of the
Creative Commons CC BY-NC license, which permits use, distribution, and
reproduction in any medium, provided the original work is properly cited.
You may not use the material for commercial purposes.</license-p>
                </license>
              </permissions>
              <abstract>
                <p>Successful hematopoietic cell transplantation (HCT) depends on rapid engraftment
of the progenitor and stem cells that will reestablish hematopoiesis. Rap1A and
Rap1B are two closely related small GTPases that may affect platelet and
neutrophil engraftment during HCT through their roles in cell adhesion and
migration. β-adrenergic signaling may regulate the participation of Rap1A and
Rap1B in engraftment through their inhibition or activation. We conducted a
correlative study of a randomized controlled trial evaluating the effects of the
nonselective β-antagonist propranolol on expression and prenylation of Rap1A and
Rap1B during neutrophil and platelet engraftment in 25 individuals receiving an
autologous HCT for multiple myeloma. Propranolol was administered for 1 week
prior to and 4 weeks following HCT. Blood was collected 7 days (baseline) and 2
days (Day -2) before HCT, and 28 days after HCT (Day +28). Circulating
polymorphonuclear cells (PMNC) were isolated and analyzed via immunoblotting to
determine levels of prenylated and total Rap1A versus Rap1B. Twelve participants
were randomized to the intervention and 13 to the control. Rap1A expression
significantly correlated with Rap1B expression. Rap1B expression significantly
correlated with slower platelet engraftment; however, this association was not
observed in the propranolol-treated group. There were no significant
associations between neutrophil engraftment and Rap1A or Rap1B expression. Post
hoc exploratory analyses did not reveal an association between social health
variables and Rap1A or Rap1B expression. This study identifies a greater
regulatory role for Rap1B than Rap1A in platelet engraftment and suggests a
possible role for β-adrenergic signaling in modulating Rap1B function during
HCT.</p>
              </abstract>
              <kwd-group>
                <kwd>Propranolol</kwd>
                <kwd>Rap1</kwd>
                <kwd>Hematopoiesis</kwd>
                <kwd>Engraftment</kwd>
                <kwd>β-adrenergic</kwd>
              </kwd-group>
            </article-meta>
          </front>
          <body>
            <sec sec-type="intro" id="s1">
              <title>Introduction</title>
              <p>Autologous Hematopoietic cell transplantation (HCT) is used as a therapeutic approach
for a variety of malignant and non-malignant blood diseases, including multiple
myeloma (MM) [<xref rid="R1" ref-type="bibr">1</xref>]. The goal of autologous HCT
is to reestablish hematopoiesis and reconstitute the immune system with “self”
hematopoietic stem and progenitor cells (HSPCs) after the patient has received
irradiation and/or chemotherapy to eliminate malignant cells and all normal
hematopoietic elements. Engraftment of platelets and neutrophils is a critical event
in HCT, with the time required for successful engraftment usually extending 10-21
days after HCT. Shortening the time required for platelet and neutrophil engraftment
allows for shorter recovery times for the hospitalized patient and faster discharge
to an outpatient setting.</p>
              <p>The small GTPases Rap1A and Rap1B are major regulators of cell adhesion and migration
[<xref rid="R2" ref-type="bibr">2</xref>-<xref rid="R7" ref-type="bibr">7</xref>] and are likely to participate in hematopoietic stem/progenitor cell
(HSPC) engraftment [<xref rid="R7" ref-type="bibr">7</xref>-<xref rid="R9" ref-type="bibr">9</xref>]. These small GTPases promote both integrin-mediated adhesion
[<xref rid="R10" ref-type="bibr">10</xref>-<xref rid="R15" ref-type="bibr">15</xref>] and cadherin-mediated adhesion [<xref rid="R16" ref-type="bibr">16</xref>-<xref rid="R18" ref-type="bibr">18</xref>], which can have varying
effects on cell migration. Rap1A and Rap1B control the adhesion and migration of
progenitor cells such as megakaryocytes [<xref rid="R10" ref-type="bibr">10</xref>,<xref rid="R13" ref-type="bibr">13</xref>,<xref rid="R19" ref-type="bibr">19</xref>,<xref rid="R20" ref-type="bibr">20</xref>], as well as
mature platelets [<xref rid="R5" ref-type="bibr">5</xref>,<xref rid="R13" ref-type="bibr">13</xref>-<xref rid="R15" ref-type="bibr">15</xref>,<xref rid="R19" ref-type="bibr">19</xref>-<xref rid="R21" ref-type="bibr">21</xref>] and
neutrophils [<xref rid="R22" ref-type="bibr">22</xref>,<xref rid="R23" ref-type="bibr">23</xref>], and are reported to participate in hematopoiesis [<xref rid="R7" ref-type="bibr">7</xref>,<xref rid="R8" ref-type="bibr">8</xref>].
Interestingly, Rap1B plays a greater role than Rap1A in platelet adhesion [<xref rid="R13" ref-type="bibr">13</xref>,<xref rid="R14" ref-type="bibr">14</xref>],
indicating that platelet engraftment potentially may be regulated more by Rap1B than
by Rap1A. Due to these important functions of Rap1A and Rap1B, the signaling events
that regulate Rap1A and Rap1B activity during HCT may impact engraftment.</p>
              <p>Signaling by β-adrenergic receptors regulates the participation of Rap1A and Rap1B in
a variety of cellular responses, including cell adhesion and migration [<xref rid="R23" ref-type="bibr">23</xref>-<xref rid="R27" ref-type="bibr">27</xref>].
The activities of Rap1A and Rap1B are increased when β-adrenergic receptors
transiently activate the guanine nucleotide exchange factor EPAC [<xref rid="R22" ref-type="bibr">22</xref>]. The activation of Rap1A and Rap1B by EPAC
enhances their participation in cell adhesion and migration [<xref rid="R11" ref-type="bibr">11</xref>,<xref rid="R12" ref-type="bibr">12</xref>,<xref rid="R22" ref-type="bibr">22</xref>,<xref rid="R28" ref-type="bibr">28</xref>,<xref rid="R29" ref-type="bibr">29</xref>]. In contrast to these
transient effects of β-adrenergic signaling, prolonged activation of β-adrenergic
receptors can inhibit Rap1A and Rap1B activity due to reduced prenylation, which is
a post-translational modification needed for these small GTPases to be active [<xref rid="R26" ref-type="bibr">26</xref>,<xref rid="R27" ref-type="bibr">27</xref>].
Reduced prenylation diminishes the participation of Rap1A and Rap1B in cell-cell
adhesion, which can alter cell migration [<xref rid="R26" ref-type="bibr">26</xref>,<xref rid="R27" ref-type="bibr">27</xref>,<xref rid="R30" ref-type="bibr">30</xref>]. β-adrenergic signaling occurs in platelets and neutrophils
[<xref rid="R31" ref-type="bibr">31</xref>-<xref rid="R35" ref-type="bibr">35</xref>] and has multiple roles in hematopoiesis [<xref rid="R36" ref-type="bibr">36</xref>-<xref rid="R39" ref-type="bibr">39</xref>]. Based on these
properties of β-adrenergic receptors, β-adrenergic signaling may modulate Rap1A and
Rap1B functions during HCT, but in currently unclear ways.</p>
              <p>Elevated stress activates β-adrenergic receptors due to the release of norepinephrine
from sympathetic neurons [<xref rid="R40" ref-type="bibr">40</xref>,<xref rid="R41" ref-type="bibr">41</xref>], and is often experienced by HCT
recipients, which can result in both transient and sustained β-adrenergic signaling
in tissues innervated by the sympathetic nervous system (SNS). Sympathetic neurons
innervate the HSPC niche in the BM [<xref rid="R38" ref-type="bibr">38</xref>,<xref rid="R42" ref-type="bibr">42</xref>] and norepinephrine released by sympathetic
neurons regulates HSPC trafficking, engraftment, and hematopoiesis [<xref rid="R43" ref-type="bibr">43</xref>-<xref rid="R45" ref-type="bibr">45</xref>].
Stress-associated social health risk factors are related to both adverse biology
[<xref rid="R46" ref-type="bibr">46</xref>-<xref rid="R50" ref-type="bibr">50</xref>] and increased mortality following HCT [<xref rid="R51" ref-type="bibr">51</xref>,<xref rid="R52" ref-type="bibr">52</xref>].
Stress-associated adverse gene expression patterns are independently associated with
increased relapse and decreased disease-free survival following allogeneic HCT
[<xref rid="R46" ref-type="bibr">46</xref>,<xref rid="R49" ref-type="bibr">49</xref>]. The impact of SNS activity on hematopoietic stem cell biology in
patients undergoing HCT may be particularly detrimental in the peri-transplantation
period [<xref rid="R53" ref-type="bibr">53</xref>,<xref rid="R54" ref-type="bibr">54</xref>]. We previously reported that blockade of β-adrenergic receptors with
propranolol improves engraftment in MM patients undergoing autologous HCT [<xref rid="R50" ref-type="bibr">50</xref>], but the roles of Rap1A and Rap1B in this
response have not been examined.</p>
              <p>The primary objective of this study was to compare the participation of Rap1A and
Rap1B in platelet and neutrophil engraftment in MM patients undergoing autologous
HCT and to examine potential changes in the small GTPases induced by propranolol
treatment. Secondary objectives included evaluating whether stress-associated social
health risk factors – including anxiety, depression, lower education, and income –
would alter Rap1A and Rap1B expression. The individual contribution of Rap1A versus
Rap1B in HCT has not been previously defined, in part because antibodies that
specifically detect Rap1A versus Rap1B have not been well characterized. We screened
a panel of commercial antibodies to identify specific antibodies that detect only
Rap1A or Rap1B. We used these specific antibodies in immunoblots to assess total
levels of the small GTPases and their prenylation status in the fraction of
platelets and polymorphonuclear cells (collectively referred to as polymorphonuclear
cells, PMNC) isolated from patients undergoing HCT, some of whom were treated with
propranolol.</p>
            </sec>
            <sec sec-type="methods" id="s2">
              <title>Methods</title>
              <sec id="s2a">
                <title>Study Design and Propranolol Treatment</title>
                <p>This study was a single site, phase II randomized controlled trial of propranolol
administration to individuals undergoing first autologous HCT for MM. The
primary aim of the parent trial was to assess whether β-blocker administration
to individuals undergoing HCT reduces CTRA gene expression and myeloid lineage
bias, thus facilitating hematopoietic recovery and improved long-term outcomes
[<xref rid="R50" ref-type="bibr">50</xref>]. Propranolol was chosen as the
preferred β-blocker given it is cost-effective, is the most studied nonselective
β-blocker [<xref rid="R55" ref-type="bibr">55</xref>], has a safe side-effect
profile, has no significant drug interactions with other drugs used in
autologous HCT for MM, and has been shown to prevent tumor progression
<italic>in vitro</italic> as compared to selective β-antagonists [<xref rid="R56" ref-type="bibr">56</xref>,<xref rid="R57" ref-type="bibr">57</xref>].</p>
                <p>The intervention group received 20 mg of propranolol orally twice daily (bid)
starting at 7 ± 2 days before transplant (baseline) and continuing until Day +28
post-transplant. Propranolol was started 7 ± 2 days prior to HCT based on mouse
model data demonstrating effective blocking of tumor β-adrenergic signaling and
progression 8 days prior to exogenous stress exposure [<xref rid="R58" ref-type="bibr">58</xref>,<xref rid="R59" ref-type="bibr">59</xref>]. Propranolol
dosing was chosen by applying human dose-finding studies to the serum
propranolol concentrations needed to diminish the adverse effects of
β-adrenergic signaling on tumor progression in mice [<xref rid="R60" ref-type="bibr">60</xref>,<xref rid="R61" ref-type="bibr">61</xref>]. Drug dosing
was adjusted after one week based on patient tolerability as assessed by the
Principal Investigator, treating HCT physician, and study coordinator.
Propranolol dosing was increased to 40 mg bid after one week if participants
were tolerating the medication and not experiencing any side effects. If
participants were able to tolerate propranolol with noticeable but less severe
side effects, they were maintained at 20 mg bid for the remainder of the study.
Patients were weaned off propranolol at the time of study completion or prior to
completion if they exhibited drug intolerance secondary to side effects and/or
new medical symptoms that resulted in a contraindication to β-blocker therapy.
Additional details regarding study drug disbursement, monitoring, follow-up
study schedule, and assessment time points were described previously [<xref rid="R48" ref-type="bibr">48</xref>].</p>
              </sec>
              <sec id="s2b">
                <title>Participant Population and Monitoring</title>
                <p>Participants selected for this study were between the ages of 18-75 years old
with MM undergoing their first autologous HCT as shown in Knight et al. Table 1
[<xref rid="R50" ref-type="bibr">50</xref>]. Further eligibility,
randomization, and exclusion criteria are detailed in Knight et al. [<xref rid="R48" ref-type="bibr">48</xref>]. The following baseline demographic
data was collected prior to study commencement: age, gender, race, income
status, and education, detailed in Knight et al. Table 1 [<xref rid="R50" ref-type="bibr">50</xref>]. The Hospital Anxiety and Depression Scale (HADS) was
collected weekly in coordination with β-blocker assessments to monitor for the
possible adverse effect of depression in the setting of propranolol
administration. Scores of 8 or above on HADS-A (7 items) and HADS-D (7 items)
connoted significant anxiety or depression, respectively; 19 patients scoring in
these ranges were contacted by the study PI and offered a referral for further
mental health care.</p>
              </sec>
              <sec id="s2c">
                <title>Identification of Specific Rap1A and Rap1B Antibodies</title>
                <p>Immunoblotting was used to screen nine commercial antibodies for reactivity with
Rap1A and Rap1B, using lysates prepared from cells overexpressing the small
GTPases. The lysates were generated by transfecting HEK293T human embryonic
kidney cells with the pcDNA3.1 expression vector encoding one of the following:
1) human Rap1A, 2) human Rap1B, 3) myc-Rap1A, which is human Rap1A with an
N-terminal myc epitope tag, 4) myc-Rap1B, which is human Rap1B with an
N-terminal myc epitope tag, 5) myc-Rap1A-SAAX, which is myc-Rap1A that cannot be
prenylated because the cysteine at aa181 is mutated to serine, or 6)
myc-Rap1B-SAAX, which is myc-Rap1B that cannot be prenylated because the
cysteine at aa181 is mutated to serine. As a negative control, HEK293T cells
were transfected only with the pcDNA 3.1 vector. After transfection of the cDNAs
using Lipofectamine 2000 (ThermoFisher, Waltham, MA, USA), the cells were
cultured for 18 hours in complete medium consisting of DMEM with 10%
heat-inactivated fetal bovine serum and antibiotics. In some cases, 15 µM
mevastatin (Sigma, St. Louis, MO, USA) was added to the cell cultures 90 minutes
after transfection of the cDNAs to prevent the expressed small GTPases from
becoming prenylated. The cells were lysed in Triton-X100/SDS lysis buffer, and
the cell lysates were subjected to SDS-PAGE, followed by transfer of the
proteins to PVDF as previously described [<xref rid="R26" ref-type="bibr">26</xref>,<xref rid="R27" ref-type="bibr">27</xref>]. The PVDF membranes
were immunoblotted using our previously reported methods [<xref rid="R26" ref-type="bibr">26</xref>,<xref rid="R27" ref-type="bibr">27</xref>] to test the
reactivity of the nine commercial Rap1A and Rap1B antibodies described in Figure 2. Among the nine antibodies that were
tested, a mouse monoclonal antibody that specifically detects Rap1A (Santa Cruz
catalog number sc-398755) and a rabbit monoclonal antibody that specifically
detects Rap1B (Cell Signaling catalog number 2326) were used for the analysis of
the patients’ samples. Prior testing revealed that these antibodies do not
differentiate between the phosphorylated and non-phosphorylated forms of Rap1
[<xref rid="R30" ref-type="bibr">30</xref>].</p>
              </sec>
              <sec id="s2d">
                <title>Collection of Patients’ PMNC and Immunoblotting</title>
                <p>A clinical research coordinator drew 8 ml of blood from each patient at each of
the three time points in the study: 7 ± 2 days before HCT (baseline), 2 days
before HCT (Day -2), and 28 days after HCT (Day +28). Among the 12 patients
receiving propranolol, treatment with propranolol was initiated immediately
after the first blood draw at the baseline collection period. The blood samples
were collected in a BD Vacutainer CPT Tube with Sodium Citrate (Fisher
Scientific Cat. No. 02-685-125). The tubes were centrifuged according to the
manufacturer’s protocol to generate a buffy layer containing mononuclear cells
and platelets (referred to as polymorphonuclear cells, PMNC). The PMNC were
lysed in Triton-X100/SDS lysis buffer, and protein concentration was determined
using the Pierce BCA Assay Kit (Pierce Cat. No 23225). For immunoblotting
analysis, 20 µg of protein from each PMNC lysate was run on a 10% SDS-PAGE gel,
transferred to PVDF, and blotted with antibodies that specifically detect Rap 1A
(Santa Cruz catalog number sc-398755) or Rap 1B (Cell Signaling catalog number
2326). Digital imaging was performed on a GE ImageQuant LAS 4000 digital imager
and densitometry determined using GE ImageQuant TL image analysis software.</p>
              </sec>
              <sec id="s2e">
                <title>Rap1 Analysis and Clinical Outcomes</title>
                <p>Comparisons were made using the densitometry values of the prenylated and
non-prenylated forms of Rap1A and Rap1B detected in the immunoblots of the
patients’ PMNC collected at baseline, Day -2, and Day +28. Total Rap1A and Rap1B
levels were log-transformed for analyses to better focus on multiplicative
effects (which correspond to additive effects on the log scale) and stabilize
the variability with varying means. Mixed effects regression analyses were
performed to explore the effects of β-blocker therapy (propranolol vs. control
groups) on total levels of Rap1A and Rap1B at each time point. The
cross-sectional correlation between log-transformed Rap1A and Rap1B was
quantified by Pearson’s correlation coefficient. Mixed effects regression models
were also used to explore the relationship between Rap1A and Rap1B at these
three time points and the patient social health risk factors – including
anxiety, depression, lower education, and income. Cox regression models were
performed to assess the relationship between log-transformed baseline Rap1A or
Rap1B expression and platelet or neutrophil engraftment time. Time to neutrophil
and platelet engraftment were defined as the first day of absolute neutrophil
count (ANC) &gt; 0.5 x 10<sup>9</sup>/L and platelet count of &gt;20 x
10<sup>9</sup>/L sustained for three consecutive assessments at least one
day apart, hereafter referred to as platelet engraftment as per standard
clinical nomenclature.</p>
              </sec>
            </sec>
            <sec sec-type="results" id="s3">
              <title>Results</title>
              <sec id="s3a">
                <title>Participant Enrollment, Demographics, and Adverse Events</title>
                <p>There were 154 patients who met initial criteria of having a planned first
autologous transplant for MM, with a final total enrollment of 25 participants
who met eligibility criteria (12 in the propranolol group, 13 in the control
group). Please see paper by Knight et al. for full recruitment details and
participant characteristics [<xref rid="R50" ref-type="bibr">50</xref>]. Of the
25 participants, there were no significant differences in their baseline
demographic, disease state, or transplant-related characteristics between the
two study groups. There were no serious adverse events experienced by
participants in either study arm [<xref rid="R50" ref-type="bibr">50</xref>].</p>
              </sec>
              <sec id="s3b">
                <title>Identification of Selective Rap1A and Rap1B Antibodies</title>
                <p>To identify an antibody that selectively detects Rap1A, and one that selectively
detects Rap1B, lysates of HEK293T cells expressing different forms of myc-tagged
or untagged Rap1A or Rap1B were immunoblotted using nine different commercial
antibodies reported to react with Rap1A and/or Rap1B (<xref rid="F1" ref-type="fig">Figure
1</xref>). These antibodies were also screened for their ability to detect
the prenylated and non-prenylated forms of the GTPases. Prenylated and
non-prenylated GTPases can be identified by their migration pattern in
immunoblots, because prenylated GTPases migrate faster than non-prenylated
GTPases during SDS-PAGE due to the greater solubility of prenylated GTPases in
SDS [<xref rid="R30" ref-type="bibr">30</xref>]. The ability of an antibody to
detect non-prenylated Rap1A or Rap1B was confirmed by the antibody reacting with
Rap1A or Rap1B isolated from cells treated with mevastatin, which inhibits
prenylation [<xref rid="R30" ref-type="bibr">30</xref>], and by the antibody
reacting with Rap1A-SAAX or Rap1B-SAAX, which are mutant forms of the GTPases
that cannot be prenylated due to serine substitution at C181 [<xref rid="R30" ref-type="bibr">30</xref>].</p>
                <p>Among the nine commercial antibodies that were tested, one antibody exhibited
greater reactivity with Rap1A than with Rap1B (<xref rid="F1" ref-type="fig">Figure 1</xref>A),
whereas another antibody exhibited greater reactivity with Rap1B than with Rap1A
(<xref rid="F1" ref-type="fig">Figure 1</xref>B). Four antibodies detected both Rap1A and
Rap1B (<xref rid="F1" ref-type="fig">Figure 1</xref>C-1F), and three antibodies
reacted with a protein that could not be attributed to Rap1A or Rap1B (<xref rid="F1" ref-type="fig">Figure 1</xref>G-1I). All antibodies that detected
prenylated Rap1A and/or Rap1B also detected the non-prenylated forms of the
GTPases, as indicated by the antibodies reacting in the immunoblots with mutant
Rap1A-SAAX and Rap1B-SAAX (lanes 4 and 8, <xref rid="F1" ref-type="fig">Figure 1</xref>) and
with Rap1A and Rap1B that had been expressed in mevastatin-treated cells (lanes
6 and 10, <xref rid="F1" ref-type="fig">Figure 1</xref>).</p>
                <p>Two antibodies were chosen for further analysis; a Rap1A-selective antibody
(Santa Cruz catalog number sc-398755, <xref rid="F1" ref-type="fig">Figure 1</xref>A) and a
Rap1B-selective antibody (Cell Signaling catalog number 2326, <xref rid="F1" ref-type="fig">Figure 1</xref>B). To compare the sensitivities of these antibodies for
Rap1A and Rap1B in the prenylated and non-prenylated forms, immunoblotting was
conducted using lysates prepared from untransfected HEK293T cells that had been
treated with or without mevastatin for 18 hours. Mevastatin was used to inhibit
the prenylation of endogenous Rap1A and Rap1B in the cells [<xref rid="R30" ref-type="bibr">30</xref>]. As seen in <xref rid="F2" ref-type="fig">Figure 2</xref>, the two antibodies exhibited similar
sensitivities for the prenylated and non-prenylated forms of endogenous Rap1A or
Rap1B expressed in the cells. Based on these immunoblotting results (Figures 1
and 2), we selected these two antibodies to examine the expression and
prenylation of Rap1A and Rap1B in the patients’ PMNC.</p>
              </sec>
              <sec id="s3c">
                <title>Analysis of Rap1A and Rap1B in Patient Samples and Correlation with Platelet
and Neutrophil Engraftment</title>
                <p>Immunoblotting of the patients’ PMNC collected at baseline, Day -2, and Day +28
indicated that expression of Rap1A and Rap1B varied extensively between
different collection times and between different patients (<xref rid="F3" ref-type="fig">Figure 3</xref>). Despite this variability, there was a
strong positive correlation between expression of Rap1A and expression of Rap1B
in the PMNC samples collected at all time points during the study. This positive
correlation between Rap1A and Rap1B expression occurred in PMNC collected at
baseline prior to propranolol treatment (r = 0.716, p &lt; 0.0001 for all 25
patients), and in PMNC collected at Day -2 and Day +28 after initiation of
propranolol treatment (r = 0.842, p = 0.0043 for the control group, and r =
0.812, p = 0.0013 for the propranolol-treated group). Rap1A and Rap1B were
prenylated in the vast majority of the patients’ samples; the slower migrating
form of Rap1A and Rap1B that indicates lack of prenylation was detected in only
one PMNC sample, collected from Patient 3 at baseline (lane 7, <xref rid="F3" ref-type="fig">Figure 3</xref>). Relative to the control group,
propranolol-treated patients did not show significantly altered levels of
prenylated Rap1A (F=0.20, p=0.82), prenylated Rap1B (F=0.90, p=0.41), or total
levels of Rap1A or Rap1B at any time points (<xref rid="F4" ref-type="fig">Figure 4</xref>).</p>
                <p>There was a strong correlation between higher Rap1B expression at baseline and
more days required for platelet engraftment (<xref rid="F5" ref-type="fig">Figure 5</xref>). This association was statistically significant when
including the results from all participants (both untreated and
propranolol-treated) in the analysis (p=0.019). Each 10-fold increase in Rap1B
at baseline was associated with a 0.4-fold decrease in the hazard of platelet
engraftment (HR=0.41; 95% CI: 0.19, 0.86; p=0.019). The correlation between
higher Rap1B expression and more days for platelet engraftment was also
statistically significant when only the results from the 13 patients who did not
receive propranolol were analyzed (HR=0.38; 95% CI: 0.15, 0.93; p=0.034).
However, this association did not reach statistical significance when the
analysis was restricted only to the results from the 12 patients who were
treated with propranolol (HR=0.78; 95% CI: 0.21, 2.9; p=0.707).</p>
                <p>In contrast to Rap1B, there was no significant correlation between baseline Rap1A
expression and the days required for platelet engraftment (HR=0.55, 95% CI:
0.27, 1.10, p=0.091) for all patients (<xref rid="F5" ref-type="fig">Figure
5</xref>). Additionally, the time required for neutrophil expression did not
significantly correlate with either Rap1A or Rap1B expression.</p>
              </sec>
              <sec id="s3d">
                <title>Post Hoc Analyses of Social Health Risk Factors</title>
                <p>Since stress promotes β-adrenergic signaling in patients undergoing HCT50, it is
possible that socially-mediated stressors would accentuate β-adrenergic effects
on Rap1A and Rap1B in these patients. To investigate this possibility, we
compared social health risk factors with Rap1A and Rap1B expression detected in
patient samples. There was no significant association between the participants’
income before diagnosis and the baseline expression of Rap1A (r=-0.37, p=0.090)
or Rap1B (r=-0.23, p=0.30), nor between the participant’s highest level of
education and the baseline expression of Rap1A (p=0.76) or Rap1B (r=.030,
p=0.89). The participants’ reported anxiety pre-transplant and post-transplant,
respectively, was not associated with Rap1A expression (r=0.28, p=0.23/r=0.030,
p=0.89) or Rap1B expression (r=0.31, p=0.19/r=-0.032, p=0.89). There was also no
significant association between the participant’s reported depression
pre-transplant or post-transplant, respectively, and the expression of Rap1A
(r=0.36, p=0.12/r=0.21, p=0.37) or Rap1B (r=0.42, p=0.07/r=0.18, p=0.44).</p>
              </sec>
            </sec>
            <sec sec-type="discussion" id="s4">
              <title>Discussion</title>
              <p>This study identifies different potential roles of Rap1A and Rap1B in platelet
engraftment after HCT. We observed that high expression of Rap1B, but not Rap1A, is
associated with more days required for platelet engraftment. This observation
supports a greater regulatory role for Rap1B than for Rap1A in platelet engraftment
after HCT, consistent with recent reports that platelet adhesion is regulated more
by Rap1B than by Rap1A [<xref rid="R5" ref-type="bibr">5</xref>,<xref rid="R14" ref-type="bibr">14</xref>]. High Rap1B expression may be a negative
regulator of platelet engraftment in patients undergoing autologous HCT.
Interestingly, this association between Rap1B and longer days to engraftment was not
observed in the propranolol-treated group, suggestive of a possible role for
β-adrenergic signaling to modulate Rap1B function during HCT.</p>
              <p>We observed unexpected variability in the expression of Rap1A and Rap1B in the
samples collected from individual patients at different times during the study. The
reasons for this variability are unclear. All samples were collected using identical
procedures, and 20 µg of protein from each patient’s PMNC sample was routinely
analyzed for immunoblotting. Thus, it seems unlikely that technical issues were
responsible for this variability. The PMNC samples that we analyzed consisted of a
mixed population of lymphocytes, granulocytes, neutrophils, and platelets obtained
from the unfractionated buffy coat. Unexplained physiologic or pathophysiologic
events occurring in this mixed population in the PMNC samples may have affected the
expression levels of Rap1B and Rap1A over the course of the study. Even though the
events that caused this variability remain unexplained, these events affected Rap1A
and Rap1B in similar ways, as indicated by the strong correlation between Rap1A
expression and Rap1B expression throughout the study.</p>
              <p>The prenylated forms of Rap1A and Rap1B predominated in almost all PMNC samples; the
non-prenylated forms of the small GTPases were detected in only one sample, which
was collected from Patient 3 at baseline (lane 7, <xref rid="F2" ref-type="fig">Figure 2</xref>). We previously described several signaling events that
suppress the prenylation of Rap1A and Rap1B [<xref rid="R26" ref-type="bibr">26</xref>,<xref rid="R27" ref-type="bibr">27</xref>,<xref rid="R30" ref-type="bibr">30</xref>]. It is possible that these signaling events were active in
the PMNC collected from Patient 3 at baseline, suppressing the prenylation of both
Rap1A and Rap1B in this sample. The lack of prior studies examining the prenylation
status of Rap1 in leukocytes provided the rationale to investigate this question, as
well as to determine if Rap1 prenylation is altered by propranolol. However, since
we observed that that nearly all Rap1 was prenylated in the patients’ PMNC samples,
future testing of the impact of propranolol on Rap1 prenylation is likely not
warranted.</p>
              <p>The signals that regulate Rap1A expression and prenylation are expected to similarly
regulate Rap1B expression and prenylation, since these two small GTPases are nearly
identical and share the same activators and effectors [<xref rid="R5" ref-type="bibr">5</xref>]. Due to their similarities, relatively few studies have
defined differences in Rap1A versus Rap1B, though they do exist. Rap1B generally
controls dynamic changes in cell-cell adhesion in response to environmental cues,
whereas Rap1A resists these cues and instead promotes steady-state, basal cell-cell
adhesion [<xref rid="R62" ref-type="bibr">62</xref>,<xref rid="R63" ref-type="bibr">63</xref>]. Consistent with the responsive nature of Rap1B, we previously
reported that Rap1B responds more than Rap1A to signaling cascades initiated by
adenosine receptors and β-adrenergic receptors [<xref rid="R27" ref-type="bibr">27</xref>]. Furthermore, platelet adhesion was recently found to be regulated
more by Rap1B than by Rap1A [<xref rid="R5" ref-type="bibr">5</xref>,<xref rid="R14" ref-type="bibr">14</xref>]. Due to these unique characteristics of
Rap1B, it is reasonable that Rap1B participates more than Rap1A in platelet
engraftment after HCT. The current study is the first to identify this in human
samples. Further, it is noteworthy this relationship persists in the setting of HCT
where the normal hematopoietic milieu is significantly altered.</p>
              <p>We found that high expression of Rap1B correlated with a longer time required for
platelet engraftment in the MM patients undergoing HCT. This finding indicates that
Rap1B negatively regulates platelet engraftment in these patients. It is possible
the signals that elevate Rap1B expression in the patients’ PMNC at baseline continue
to impact Rap1B during engraftment, promoting Rap1B-mediated events that slow
engraftment. Multiple events undoubtedly contribute to the negative regulation of
platelet engraftment by Rap1B, most likely involving the Rap1B-mediated regulation
of cell adhesion and migration. Increased expression and/or activity of Rap1B can
enhance cell-cell adhesion [<xref rid="R16" ref-type="bibr">16</xref>-<xref rid="R18" ref-type="bibr">18</xref>], which might negatively affect specific
steps during platelet engraftment that require cell migration.</p>
              <p>In patients undergoing HCT, elevated stress and the norepinephrine-mediated
activation of β-adrenergic receptors may regulate Rap1B activity during HPSC
migration and engraftment. β-adrenergic signaling can have opposing effects on Rap1B
activity, depending on the duration of the signaling event. Transient β-adrenergic
signaling activates Rap1B through EPAC [<xref rid="R11" ref-type="bibr">11</xref>,<xref rid="R12" ref-type="bibr">12</xref>,<xref rid="R22" ref-type="bibr">22</xref>,<xref rid="R28" ref-type="bibr">28</xref>,<xref rid="R29" ref-type="bibr">29</xref>], while sustained β-adrenergic signaling
inhibits Rap1B by suppressing its prenylation [<xref rid="R26" ref-type="bibr">26</xref>,<xref rid="R27" ref-type="bibr">27</xref>]. It is unlikely that Rap1B
was inhibited by β-adrenergic signaling in this study, since Rap1B was prenylated in
the majority of the patients’ samples. Instead, β-adrenergic signaling most likely
activated Rap1B, which may have increased the ability of Rap1B to promote cell-cell
adhesion and slow engraftment. It is through inhibition of this β-adrenergic
signaling that propranolol may disassociate the negative effect of Rap1B on platelet
engraftment. This is consistent with other clinical studies demonstrating that
adrenergic input may worsen MM outcomes [<xref rid="R64" ref-type="bibr">64</xref>,<xref rid="R65" ref-type="bibr">65</xref>], while β-blockade may
improve them [<xref rid="R50" ref-type="bibr">50</xref>]. Given the integral role of
stress in this pathway, future studies utilizing catecholamines and/or cortisol as
physiologic measurements of stress could provide a useful complementary approach to
its assessment.</p>
              <p>Our observation that high Rap1B expression significantly correlates with slower
platelet engraftment for untreated patients, but not for propranolol-treated
patients, is suggestive of the potential utility of propranolol for use in aiding
engraftment. However, interpretation of these findings is limited due to small
sample size and subsequent lack of statistical comparison between the two groups. As
such, these findings do not definitively prove that Rap1B mediates any effect of
propranolol on this process. Nevertheless, these findings support the development of
future studies using a larger sample size to determine if antagonism of β-adrenergic
signaling may inhibit Rap1B activity and subsequently hasten engraftment. Evidence
to continue this area of investigation is further corroborated by studies
demonstrating the clinically meaningful impact of propranolol on earlier platelet
engraftment [<xref rid="R50" ref-type="bibr">50</xref>] and would help identify
candidate components of affected signaling pathways.</p>
              <p>We previously reported that inhibiting β-adrenergic signaling using propranolol
improves engraftment in MM patients undergoing HCT [<xref rid="R50" ref-type="bibr">50</xref>]. By studying Rap1A and Rap1B, we have identified Rap1B as a
potential mechanistic molecule regulating platelet engraftment after HCT. Future
studies are needed to further define Rap1B as a participant in the
β-adrenergic-mediated signaling cascade that diminishes successful HCT.</p>
            </sec>
          </body>
          <back>
            <ack>
              <p>This work was funded in part by the National Cancer Institute (NCI) Contract No.
HHSN261200800001E and the NCI Network on Biobehavioral Pathways in Cancer; the
National Center for Advancing Translational Sciences, National Institutes of Health
(NIH), through Grant Numbers UL1TR001436, KL2TR001438 and R03 HL155174; Medical
College of Wisconsin Institutional Research Grant #86-004-26 from the American
Cancer Society; and the Laura Gralton Philanthropic Fund. These studies were also
supported by funding from NCI R01CA238562 (JMK), NCI R01 BA188871 (CLW), and NCI R01
CA204231 (SR).</p>
            </ack>
            <notes>
              <title>Author Contributions</title>
              <p>Designed research: JMK, CLW; Performed Research: JMK, AKJ, CLW, ELL; Contributed
vital new reagents or analytical tools: CLW; Collected Data: JMK, CLW, NNS, AD, SC,
MH, BD, PH; Analyzed and interpreted data: AKJ, JMK, CLW, ELL, SR, KC; Performed
statistical analysis: AS, RW; Manuscript writing: AKJ, JMK, CLW, AS, NNS, AD, SC,
MH, BD, PH, SR, KC.</p>
            </notes>
            <glossary>
              <def-list>
                <def-item>
                  <term>HCT</term>
                  <def>
                    <p>Hematopoietic cell transplantation</p>
                  </def>
                </def-item>
                <def-item>
                  <term>MM</term>
                  <def>
                    <p>multiple myeloma</p>
                  </def>
                </def-item>
                <def-item>
                  <term>HSPCs</term>
                  <def>
                    <p>hematopoietic stem and progenitor cells</p>
                  </def>
                </def-item>
                <def-item>
                  <term>SNS</term>
                  <def>
                    <p>sympathetic nervous system</p>
                  </def>
                </def-item>
                <def-item>
                  <term>PMNC</term>
                  <def>
                    <p>polymorphonuclear cells</p>
                  </def>
                </def-item>
                <def-item>
                  <term>HADS</term>
                  <def>
                    <p>Hospital Anxiety and Depression Scale</p>
                  </def>
                </def-item>
              </def-list>
            </glossary>
            <ref-list>
              <ref id="R1">
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Kanate</surname><given-names>AS</given-names></string-name><string-name><surname>Majhail</surname><given-names>NS</given-names></string-name><string-name><surname>Savani</surname><given-names>BN</given-names></string-name><string-name><surname>Bredeson</surname><given-names>C</given-names></string-name><string-name><surname>Champlin</surname><given-names>RE</given-names></string-name><string-name><surname>Crawford</surname><given-names>S</given-names></string-name><etal>et al.</etal></person-group><article-title>Indications for Hematopoietic Cell Transplantation and Immune
Effector Cell Therapy: Guidelines from the American Society for
Transplantation and Cellular Therapy</article-title>. <source>Biol Blood
Marrow Transplant</source>. <year>2020</year><month>Jul</month>;<volume>26</volume>(<issue>7</issue>):<fpage>1247</fpage>–<lpage>56</lpage>.
<pub-id pub-id-type="doi">10.1016/j.bbmt.2020.03.002</pub-id><issn>1523-6536</issn><?supplied-pmid 32165328?><pub-id pub-id-type="pmid">32165328</pub-id></mixed-citation>
              </ref>
              <ref id="R2">
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Bos</surname><given-names>JL</given-names></string-name><string-name><surname>de Bruyn</surname><given-names>K</given-names></string-name><string-name><surname>Enserink</surname><given-names>J</given-names></string-name><string-name><surname>Kuiperij</surname><given-names>B</given-names></string-name><string-name><surname>Rangarajan</surname><given-names>S</given-names></string-name><string-name><surname>Rehmann</surname><given-names>H</given-names></string-name><etal>et al.</etal></person-group><article-title>The role of Rap1 in integrin-mediated cell
adhesion</article-title>. <source>Biochem Soc Trans</source>.
<year>2003</year><month>Feb</month>;<volume>31</volume>(<issue>Pt
1</issue>):<fpage>83</fpage>–<lpage>6</lpage>. <pub-id pub-id-type="doi">10.1042/bst0310083</pub-id><issn>0300-5127</issn><?supplied-pmid 12546659?><pub-id pub-id-type="pmid">12546659</pub-id></mixed-citation>
              </ref>
              <ref id="R3">
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Kinashi</surname><given-names>T</given-names></string-name><string-name><surname>Katagiri</surname><given-names>K</given-names></string-name></person-group>. <article-title>Regulation of lymphocyte adhesion and migration
by the small GTPase Rap1 and its effector molecule, RAPL</article-title>.
<source>Immunol Lett</source>. <year>2004</year><month>Apr</month>;<volume>93</volume>(<issue>1</issue>):<fpage>1</fpage>–<lpage>5</lpage>.
<pub-id pub-id-type="doi">10.1016/j.imlet.2004.02.008</pub-id><issn>0165-2478</issn><?supplied-pmid 15134891?><pub-id pub-id-type="pmid">15134891</pub-id></mixed-citation>
              </ref>
              <ref id="R4">
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Bos</surname><given-names>JL</given-names></string-name></person-group>. <article-title>Linking Rap to cell adhesion</article-title>.
<source>Curr Opin Cell Biol</source>. <year>2005</year><month>Apr</month>;<volume>17</volume>(<issue>2</issue>):<fpage>123</fpage>–<lpage>8</lpage>.
<pub-id pub-id-type="doi">10.1016/j.ceb.2005.02.00</pub-id>
<pub-id pub-id-type="doi">10.1016/j.ceb.2005.02.009</pub-id><issn>0955-0674</issn><?supplied-pmid 15780587?><pub-id pub-id-type="pmid">15780587</pub-id></mixed-citation>
              </ref>
              <ref id="R5">
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Stefanini</surname><given-names>L</given-names></string-name><string-name><surname>Bergmeier</surname><given-names>W</given-names></string-name></person-group>. <article-title>RAP GTPases and platelet integrin
signaling</article-title>. <source>Platelets</source>.
<year>2019</year>;<volume>30</volume>(<issue>1</issue>):<fpage>41</fpage>–<lpage>7</lpage>.
<pub-id pub-id-type="doi">10.1080/09537104.2018.1476681</pub-id><issn>1369-1635</issn><?supplied-pmid 29863951?><pub-id pub-id-type="pmid">29863951</pub-id></mixed-citation>
              </ref>
              <ref id="R6">
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Lagarrigue</surname><given-names>F</given-names></string-name><string-name><surname>Kim</surname><given-names>C</given-names></string-name><string-name><surname>Ginsberg</surname><given-names>MH</given-names></string-name></person-group>. <article-title>The Rap1-RIAM-talin axis of integrin activation
and blood cell function</article-title>. <source>Blood</source>.
<year>2016</year><month>Jul</month>;<volume>128</volume>(<issue>4</issue>):<fpage>479</fpage>–<lpage>87</lpage>.
<pub-id pub-id-type="doi">10.1182/blood-2015-12-638700</pub-id><issn>1528-0020</issn><?supplied-pmid 27207789?><pub-id pub-id-type="pmid">27207789</pub-id></mixed-citation>
              </ref>
              <ref id="R7">
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Stork</surname><given-names>PJ</given-names></string-name><string-name><surname>Dillon</surname><given-names>TJ</given-names></string-name></person-group>. <article-title>Multiple roles of Rap1 in hematopoietic cells:
complementary versus antagonistic functions</article-title>.
<source>Blood</source>. <year>2005</year><month>Nov</month>;<volume>106</volume>(<issue>9</issue>):<fpage>2952</fpage>–<lpage>61</lpage>.
<pub-id pub-id-type="doi">10.1182/blood-2005-03-1062</pub-id><issn>0006-4971</issn><?supplied-pmid 16076873?><pub-id pub-id-type="pmid">16076873</pub-id></mixed-citation>
              </ref>
              <ref id="R8">
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Minato</surname><given-names>N</given-names></string-name><string-name><surname>Kometani</surname><given-names>K</given-names></string-name><string-name><surname>Hattori</surname><given-names>M</given-names></string-name></person-group>. <article-title>Regulation of immune responses and hematopoiesis
by the Rap1 signal</article-title>. <source>Adv Immunol</source>.
<year>2007</year>;<volume>93</volume>:<fpage>229</fpage>–<lpage>64</lpage>.
<pub-id pub-id-type="doi">10.1016/S0065-2776(06)93006-5</pub-id><issn>0065-2776</issn><?supplied-pmid 17383543?><pub-id pub-id-type="pmid">17383543</pub-id></mixed-citation>
              </ref>
              <ref id="R9">
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Imai</surname><given-names>T</given-names></string-name><string-name><surname>Tanaka</surname><given-names>H</given-names></string-name><string-name><surname>Hamazaki</surname><given-names>Y</given-names></string-name><string-name><surname>Minato</surname><given-names>N</given-names></string-name></person-group>. <article-title>Rap1 signal modulators control the maintenance
of hematopoietic progenitors in bone marrow and adult long-term
hematopoiesis</article-title>. <source>Cancer Sci</source>.
<year>2019</year><month>Apr</month>;<volume>110</volume>(<issue>4</issue>):<fpage>1317</fpage>–<lpage>30</lpage>.
<pub-id pub-id-type="doi">10.1111/cas.13974</pub-id><issn>1349-7006</issn><?supplied-pmid 30767320?><pub-id pub-id-type="pmid">30767320</pub-id></mixed-citation>
              </ref>
              <ref id="R10">
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>de Bruyn</surname><given-names>KM</given-names></string-name><string-name><surname>Zwartkruis</surname><given-names>FJ</given-names></string-name><string-name><surname>de Rooij</surname><given-names>J</given-names></string-name><string-name><surname>Akkerman</surname><given-names>JW</given-names></string-name><string-name><surname>Bos</surname><given-names>JL</given-names></string-name></person-group>. <article-title>The small GTPase Rap1 is activated by turbulence
and is involved in integrin [alpha]IIb[beta]3-mediated cell adhesion in
human megakaryocytes</article-title>. <source>J Biol Chem</source>.
<year>2003</year><month>Jun</month>;<volume>278</volume>(<issue>25</issue>):<fpage>22412</fpage>–<lpage>7</lpage>.
<pub-id pub-id-type="doi">10.1074/jbc.M212036200</pub-id><issn>0021-9258</issn><?supplied-pmid 12690117?><pub-id pub-id-type="pmid">12690117</pub-id></mixed-citation>
              </ref>
              <ref id="R11">
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Rangarajan</surname><given-names>S</given-names></string-name><string-name><surname>Enserink</surname><given-names>JM</given-names></string-name><string-name><surname>Kuiperij</surname><given-names>HB</given-names></string-name><string-name><surname>de Rooij</surname><given-names>J</given-names></string-name><string-name><surname>Price</surname><given-names>LS</given-names></string-name><string-name><surname>Schwede</surname><given-names>F</given-names></string-name><etal>et al.</etal></person-group><article-title>Cyclic AMP induces integrin-mediated cell adhesion through Epac
and Rap1 upon stimulation of the beta 2-adrenergic receptor</article-title>.
<source>J Cell Biol</source>. <year>2003</year><month>Feb</month>;<volume>160</volume>(<issue>4</issue>):<fpage>487</fpage>–<lpage>93</lpage>.
<pub-id pub-id-type="doi">10.1083/jcb.200209105</pub-id><issn>0021-9525</issn><?supplied-pmid 12578910?><pub-id pub-id-type="pmid">12578910</pub-id></mixed-citation>
              </ref>
              <ref id="R12">
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Enserink</surname><given-names>JM</given-names></string-name><string-name><surname>Price</surname><given-names>LS</given-names></string-name><string-name><surname>Methi</surname><given-names>T</given-names></string-name><string-name><surname>Mahic</surname><given-names>M</given-names></string-name><string-name><surname>Sonnenberg</surname><given-names>A</given-names></string-name><string-name><surname>Bos</surname><given-names>JL</given-names></string-name><etal>et al.</etal></person-group><article-title>The cAMP-Epac-Rap1 pathway regulates cell spreading and cell
adhesion to laminin-5 through the alpha3beta1 integrin but not the
alpha6beta4 integrin</article-title>. <source>J Biol Chem</source>.
<year>2004</year><month>Oct</month>;<volume>279</volume>(<issue>43</issue>):<fpage>44889</fpage>–<lpage>96</lpage>.
<pub-id pub-id-type="doi">10.1074/jbc.M404599200</pub-id><issn>0021-9258</issn><?supplied-pmid 15302884?><pub-id pub-id-type="pmid">15302884</pub-id></mixed-citation>
              </ref>
              <ref id="R13">
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Stefanini</surname><given-names>L</given-names></string-name><string-name><surname>Lee</surname><given-names>RH</given-names></string-name><string-name><surname>Paul</surname><given-names>DS</given-names></string-name><string-name><surname>O’Shaughnessy</surname><given-names>EC</given-names></string-name><string-name><surname>Ghalloussi</surname><given-names>D</given-names></string-name><string-name><surname>Jones</surname><given-names>CI</given-names></string-name><etal>et al.</etal></person-group><article-title>Functional redundancy between RAP1 isoforms in murine platelet
production and function</article-title>. <source>Blood</source>.
<year>2018</year><month>Nov</month>;<volume>132</volume>(<issue>18</issue>):<fpage>1951</fpage>–<lpage>62</lpage>.
<pub-id pub-id-type="doi">10.1182/blood-2018-03-838714</pub-id><issn>1528-0020</issn><?supplied-pmid 30131434?><pub-id pub-id-type="pmid">30131434</pub-id></mixed-citation>
              </ref>
              <ref id="R14">
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Nieman</surname><given-names>MT</given-names></string-name></person-group>. <article-title>RAPid signaling in platelets</article-title>.
<source>Blood</source>. <year>2018</year><month>Nov</month>;<volume>132</volume>(<issue>18</issue>):<fpage>1864</fpage>–<lpage>5</lpage>.
<pub-id pub-id-type="doi">10.1182/blood-2018-09-872093</pub-id><issn>1528-0020</issn><?supplied-pmid 30385489?><pub-id pub-id-type="pmid">30385489</pub-id></mixed-citation>
              </ref>
              <ref id="R15">
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Bromberger</surname><given-names>T</given-names></string-name><string-name><surname>Klapproth</surname><given-names>S</given-names></string-name><string-name><surname>Rohwedder</surname><given-names>I</given-names></string-name><string-name><surname>Zhu</surname><given-names>L</given-names></string-name><string-name><surname>Mittmann</surname><given-names>L</given-names></string-name><string-name><surname>Reichel</surname><given-names>CA</given-names></string-name><etal>et al.</etal></person-group><article-title>Direct Rap1/Talin1 interaction regulates platelet and neutrophil
integrin activity in mice</article-title>. <source>Blood</source>.
<year>2018</year><month>Dec</month>;<volume>132</volume>(<issue>26</issue>):<fpage>2754</fpage>–<lpage>62</lpage>.
<pub-id pub-id-type="doi">10.1182/blood-2018-04-846766</pub-id><issn>1528-0020</issn><?supplied-pmid 30442677?><pub-id pub-id-type="pmid">30442677</pub-id></mixed-citation>
              </ref>
              <ref id="R16">
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Price</surname><given-names>LS</given-names></string-name><string-name><surname>Hajdo-Milasinovic</surname><given-names>A</given-names></string-name><string-name><surname>Zhao</surname><given-names>J</given-names></string-name><string-name><surname>Zwartkruis</surname><given-names>FJ</given-names></string-name><string-name><surname>Collard</surname><given-names>JG</given-names></string-name><string-name><surname>Bos</surname><given-names>JL</given-names></string-name></person-group>. <article-title>Rap1 regulates E-cadherin-mediated cell-cell
adhesion</article-title>. <source>J Biol Chem</source>. <year>2004</year><month>Aug</month>;<volume>279</volume>(<issue>34</issue>):<fpage>35127</fpage>–<lpage>32</lpage>.
<pub-id pub-id-type="doi">10.1074/jbc.M404917200</pub-id><issn>0021-9258</issn><?supplied-pmid 15166221?><pub-id pub-id-type="pmid">15166221</pub-id></mixed-citation>
              </ref>
              <ref id="R17">
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Hogan</surname><given-names>C</given-names></string-name><string-name><surname>Serpente</surname><given-names>N</given-names></string-name><string-name><surname>Cogram</surname><given-names>P</given-names></string-name><string-name><surname>Hosking</surname><given-names>CR</given-names></string-name><string-name><surname>Bialucha</surname><given-names>CU</given-names></string-name><string-name><surname>Feller</surname><given-names>SM</given-names></string-name><etal>et al.</etal></person-group><article-title>Rap1 regulates the formation of E-cadherin-based cell-cell
contacts</article-title>. <source>Mol Cell Biol</source>. <year>2004</year><month>Aug</month>;<volume>24</volume>(<issue>15</issue>):<fpage>6690</fpage>–<lpage>700</lpage>.
<pub-id pub-id-type="doi">10.1128/MCB.24.15.6690-6700.2004</pub-id><issn>0270-7306</issn><?supplied-pmid 15254236?><pub-id pub-id-type="pmid">15254236</pub-id></mixed-citation>
              </ref>
              <ref id="R18">
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Kooistra</surname><given-names>MR</given-names></string-name><string-name><surname>Dubé</surname><given-names>N</given-names></string-name><string-name><surname>Bos</surname><given-names>JL</given-names></string-name></person-group>. <article-title>Rap1: a key regulator in cell-cell junction
formation</article-title>. <source>J Cell Sci</source>. <year>2007</year><month>Jan</month>;<volume>120</volume>(<issue>Pt
1</issue>):<fpage>17</fpage>–<lpage>22</lpage>. <pub-id pub-id-type="doi">10.1242/jcs.03306</pub-id><issn>0021-9533</issn><?supplied-pmid 17182900?><pub-id pub-id-type="pmid">17182900</pub-id></mixed-citation>
              </ref>
              <ref id="R19">
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Molina-Ortiz</surname><given-names>P</given-names></string-name><string-name><surname>Polizzi</surname><given-names>S</given-names></string-name><string-name><surname>Ramery</surname><given-names>E</given-names></string-name><string-name><surname>Gayral</surname><given-names>S</given-names></string-name><string-name><surname>Delierneux</surname><given-names>C</given-names></string-name><string-name><surname>Oury</surname><given-names>C</given-names></string-name><etal>et al.</etal></person-group><article-title>Rasa3 controls megakaryocyte Rap1 activation, integrin signaling
and differentiation into proplatelet</article-title>. <source>PLoS
Genet</source>. <year>2014</year><month>Jun</month>;<volume>10</volume>(<issue>6</issue>):<fpage>e1004420</fpage>.
<pub-id pub-id-type="doi">10.1371/journal.pgen.1004420</pub-id><issn>1553-7404</issn><?supplied-pmid 24967784?><pub-id pub-id-type="pmid">24967784</pub-id></mixed-citation>
              </ref>
              <ref id="R20">
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Ortiz-Rivero</surname><given-names>S</given-names></string-name><string-name><surname>Baquero</surname><given-names>C</given-names></string-name><string-name><surname>Hernández-Cano</surname><given-names>L</given-names></string-name><string-name><surname>Roldán-Etcheverry</surname><given-names>JJ</given-names></string-name><string-name><surname>Gutiérrez-Herrero</surname><given-names>S</given-names></string-name><string-name><surname>Fernández-Infante</surname><given-names>C</given-names></string-name><etal>et al.</etal></person-group><article-title>C3G, through its GEF activity, induces megakaryocytic
differentiation and proplatelet formation</article-title>. <source>Cell
Commun Signal</source>. <year>2018</year><month>Dec</month>;<volume>16</volume>(<issue>1</issue>):<fpage>101</fpage>.
<pub-id pub-id-type="doi">10.1186/s12964-018-0311-5</pub-id><issn>1478-811X</issn><?supplied-pmid 30567575?><pub-id pub-id-type="pmid">30567575</pub-id></mixed-citation>
              </ref>
              <ref id="R21">
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Hackeng</surname><given-names>CM</given-names></string-name><string-name><surname>Franke</surname><given-names>B</given-names></string-name><string-name><surname>Relou</surname><given-names>IA</given-names></string-name><string-name><surname>Gorter</surname><given-names>G</given-names></string-name><string-name><surname>Bos</surname><given-names>JL</given-names></string-name><string-name><surname>van Rijn</surname><given-names>HJ</given-names></string-name><etal>et al.</etal></person-group><article-title>Low-density lipoprotein activates the small GTPases Rap1 and Ral
in human platelets</article-title>. <source>Biochem J</source>.
<year>2000</year><month>Jul</month>;<volume>349</volume>(<issue>Pt
1</issue>):<fpage>231</fpage>–<lpage>8</lpage>. <pub-id pub-id-type="doi">10.1042/0264-6021:3490231</pub-id>
<pub-id pub-id-type="doi">10.1042/bj3490231</pub-id><issn>0264-6021</issn><?supplied-pmid 10861233?><pub-id pub-id-type="pmid">10861233</pub-id></mixed-citation>
              </ref>
              <ref id="R22">
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Dash-Koney</surname><given-names>M</given-names></string-name><string-name><surname>Deevi</surname><given-names>RK</given-names></string-name><string-name><surname>McFarlane</surname><given-names>C</given-names></string-name><string-name><surname>Dib</surname><given-names>K</given-names></string-name></person-group>. <article-title>Exchange protein directly activated by cAMP 1
(Epac1) is expressed in human neutrophils and mediates cAMP-dependent
activation of the monomeric GTPase Rap1</article-title>. <source>J Leukoc
Biol</source>. <year>2011</year><month>Oct</month>;<volume>90</volume>(<issue>4</issue>):<fpage>741</fpage>–<lpage>9</lpage>.
<pub-id pub-id-type="doi">10.1189/jlb.0211108</pub-id><issn>1938-3673</issn><?supplied-pmid 21750123?><pub-id pub-id-type="pmid">21750123</pub-id></mixed-citation>
              </ref>
              <ref id="R23">
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Scott</surname><given-names>J</given-names></string-name><string-name><surname>Harris</surname><given-names>GJ</given-names></string-name><string-name><surname>Pinder</surname><given-names>EM</given-names></string-name><string-name><surname>Macfarlane</surname><given-names>JG</given-names></string-name><string-name><surname>Hellyer</surname><given-names>TP</given-names></string-name><string-name><surname>Rostron</surname><given-names>AJ</given-names></string-name><etal>et al.</etal></person-group><article-title>Exchange protein directly activated by cyclic AMP (EPAC)
activation reverses neutrophil dysfunction induced by β2-agonists,
corticosteroids, and critical illness</article-title>. <source>J Allergy
Clin Immunol</source>. <year>2016</year><month>Feb</month>;<volume>137</volume>(<issue>2</issue>):<fpage>535</fpage>–<lpage>44</lpage>.
<pub-id pub-id-type="doi">10.1016/j.jaci.2015.07.036</pub-id><issn>1097-6825</issn><?supplied-pmid 26388312?><pub-id pub-id-type="pmid">26388312</pub-id></mixed-citation>
              </ref>
              <ref id="R24">
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Bastian</surname><given-names>P</given-names></string-name><string-name><surname>Balcarek</surname><given-names>A</given-names></string-name><string-name><surname>Altanis</surname><given-names>C</given-names></string-name><string-name><surname>Strell</surname><given-names>C</given-names></string-name><string-name><surname>Niggemann</surname><given-names>B</given-names></string-name><string-name><surname>Zaenker</surname><given-names>KS</given-names></string-name><etal>et al.</etal></person-group><article-title>The inhibitory effect of norepinephrine on the migration of ES-2
ovarian carcinoma cells involves a Rap1-dependent pathway</article-title>.
<source>Cancer Lett</source>. <year>2009</year><month>Feb</month>;<volume>274</volume>(<issue>2</issue>):<fpage>218</fpage>–<lpage>24</lpage>.
<pub-id pub-id-type="doi">10.1016/j.canlet.2008.09.008</pub-id><issn>1872-7980</issn><?supplied-pmid 18849110?><pub-id pub-id-type="pmid">18849110</pub-id></mixed-citation>
              </ref>
              <ref id="R25">
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Steininger</surname><given-names>TS</given-names></string-name><string-name><surname>Stutz</surname><given-names>H</given-names></string-name><string-name><surname>Kerschbaum</surname><given-names>HH</given-names></string-name></person-group>. <article-title>Beta-adrenergic stimulation suppresses
phagocytosis via Epac activation in murine microglial cells</article-title>.
<source>Brain Res</source>. <year>2011</year><month>Aug</month>;<volume>1407</volume>:<fpage>1</fpage>–<lpage>12</lpage>.
<pub-id pub-id-type="doi">10.1016/j.brainres.2011.06.050</pub-id><issn>1872-6240</issn><?supplied-pmid 21763641?><pub-id pub-id-type="pmid">21763641</pub-id></mixed-citation>
              </ref>
              <ref id="R26">
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Wilson</surname><given-names>JM</given-names></string-name><string-name><surname>Lorimer</surname><given-names>E</given-names></string-name><string-name><surname>Tyburski</surname><given-names>MD</given-names></string-name><string-name><surname>Williams</surname><given-names>CL</given-names></string-name></person-group>. <article-title>β-Adrenergic receptors suppress Rap1B
prenylation and promote the metastatic phenotype in breast cancer
cells</article-title>. <source>Cancer Biol Ther</source>.
<year>2015</year>;<volume>16</volume>(<issue>9</issue>):<fpage>1364</fpage>–<lpage>74</lpage>.
<pub-id pub-id-type="doi">10.1080/15384047.2015.1070988</pub-id><issn>1555-8576</issn><?supplied-pmid 26209110?><pub-id pub-id-type="pmid">26209110</pub-id></mixed-citation>
              </ref>
              <ref id="R27">
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Wilson</surname><given-names>JM</given-names></string-name><string-name><surname>Prokop</surname><given-names>JW</given-names></string-name><string-name><surname>Lorimer</surname><given-names>E</given-names></string-name><string-name><surname>Ntantie</surname><given-names>E</given-names></string-name><string-name><surname>Williams</surname><given-names>CL</given-names></string-name></person-group>. <article-title>Differences in the Phosphorylation-Dependent
Regulation of Prenylation of Rap1A and Rap1B</article-title>. <source>J Mol
Biol</source>. <year>2016</year><month>Dec</month>;<volume>428</volume>(<issue>24</issue><supplement>24 Pt B</supplement>):<fpage>4929</fpage>–<lpage>45</lpage>. <pub-id pub-id-type="doi">10.1016/j.jmb.2016.10.016</pub-id><issn>1089-8638</issn><?supplied-pmid 27760305?><pub-id pub-id-type="pmid">27760305</pub-id></mixed-citation>
              </ref>
              <ref id="R28">
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Bos</surname><given-names>JL</given-names></string-name></person-group>. <article-title>Epac proteins: multi-purpose cAMP
targets</article-title><comment>[published correction appears in Trends Biochem Sci. 2007
Jan;32(1):5]</comment>. <source>Trends Biochem Sci</source>.
<year>2006</year><month>Dec</month>;<volume>31</volume>(<issue>12</issue>):<fpage>680</fpage>–<lpage>6</lpage>.
<pub-id pub-id-type="doi">10.1016/j.tibs.2006.10.002</pub-id><issn>0968-0004</issn><?supplied-pmid 17084085?><pub-id pub-id-type="pmid">17084085</pub-id></mixed-citation>
              </ref>
              <ref id="R29">
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Holz</surname><given-names>GG</given-names></string-name><string-name><surname>Kang</surname><given-names>G</given-names></string-name><string-name><surname>Harbeck</surname><given-names>M</given-names></string-name><string-name><surname>Roe</surname><given-names>MW</given-names></string-name><string-name><surname>Chepurny</surname><given-names>OG</given-names></string-name></person-group>. <article-title>Cell physiology of cAMP sensor
Epac</article-title>. <source>J Physiol</source>. <year>2006</year><month>Nov</month>;<volume>577</volume>(<issue>Pt
1</issue>):<fpage>5</fpage>–<lpage>15</lpage>. <pub-id pub-id-type="doi">10.1113/jphysiol.2006.119644</pub-id><issn>0022-3751</issn><?supplied-pmid 16973695?><pub-id pub-id-type="pmid">16973695</pub-id></mixed-citation>
              </ref>
              <ref id="R30">
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Ntantie</surname><given-names>E</given-names></string-name><string-name><surname>Gonyo</surname><given-names>P</given-names></string-name><string-name><surname>Lorimer</surname><given-names>EL</given-names></string-name><string-name><surname>Hauser</surname><given-names>AD</given-names></string-name><string-name><surname>Schuld</surname><given-names>N</given-names></string-name><string-name><surname>McAllister</surname><given-names>D</given-names></string-name><etal>et al.</etal></person-group><article-title>An adenosine-mediated signaling pathway suppresses prenylation of
the GTPase Rap1B and promotes cell scattering</article-title>. <source>Sci
Signal</source>. <year>2013</year><month>May</month>;<volume>6</volume>(<issue>277</issue>):<fpage>ra39</fpage>.
<pub-id pub-id-type="doi">10.1126/scisignal.2003374</pub-id><issn>1937-9145</issn><?supplied-pmid 23716716?><pub-id pub-id-type="pmid">23716716</pub-id></mixed-citation>
              </ref>
              <ref id="R31">
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Hjemdahl</surname><given-names>P</given-names></string-name><string-name><surname>Larsson</surname><given-names>PT</given-names></string-name><string-name><surname>Wallén</surname><given-names>NH</given-names></string-name></person-group>. <article-title>Effects of stress and beta-blockade on platelet
function</article-title>. <source>Circulation</source>. <year>1991</year><month>Dec</month>;<volume>84</volume>(<issue>6</issue><supplement>Suppl</supplement>):<fpage>VI44</fpage>–<lpage>61</lpage>.<issn>0009-7322</issn><?supplied-pmid 1683610?><pub-id pub-id-type="pmid">1683610</pub-id></mixed-citation>
              </ref>
              <ref id="R32">
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Larsson</surname><given-names>PT</given-names></string-name><string-name><surname>Wallén</surname><given-names>NH</given-names></string-name><string-name><surname>Martinsson</surname><given-names>A</given-names></string-name><string-name><surname>Egberg</surname><given-names>N</given-names></string-name><string-name><surname>Hjemdahl</surname><given-names>P</given-names></string-name></person-group>. <article-title>Significance of platelet beta-adrenoceptors for
platelet responses in vivo and in vitro</article-title>. <source>Thromb
Haemost</source>. <year>1992</year><month>Dec</month>;<volume>68</volume>(<issue>6</issue>):<fpage>687</fpage>–<lpage>93</lpage>.
<pub-id pub-id-type="doi">10.1055/s-0038-1646345</pub-id><issn>0340-6245</issn><?supplied-pmid 1337630?><pub-id pub-id-type="pmid">1337630</pub-id></mixed-citation>
              </ref>
              <ref id="R33">
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Bonten</surname><given-names>TN</given-names></string-name><string-name><surname>Plaizier</surname><given-names>CE</given-names></string-name><string-name><surname>Snoep</surname><given-names>JJ</given-names></string-name><string-name><surname>Stijnen</surname><given-names>T</given-names></string-name><string-name><surname>Dekkers</surname><given-names>OM</given-names></string-name><string-name><surname>van der Bom</surname><given-names>JG</given-names></string-name></person-group>. <article-title>Effect of β-blockers on platelet aggregation: a
systematic review and meta-analysis</article-title>. <source>Br J Clin
Pharmacol</source>. <year>2014</year><month>Nov</month>;<volume>78</volume>(<issue>5</issue>):<fpage>940</fpage>–<lpage>9</lpage>.
<pub-id pub-id-type="doi">10.1111/bcp.12404</pub-id><issn>1365-2125</issn><?supplied-pmid 24730697?><pub-id pub-id-type="pmid">24730697</pub-id></mixed-citation>
              </ref>
              <ref id="R34">
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Nicholls</surname><given-names>AJ</given-names></string-name><string-name><surname>Wen</surname><given-names>SW</given-names></string-name><string-name><surname>Hall</surname><given-names>P</given-names></string-name><string-name><surname>Hickey</surname><given-names>MJ</given-names></string-name><string-name><surname>Wong</surname><given-names>CH</given-names></string-name></person-group>. <article-title>Activation of the sympathetic nervous system
modulates neutrophil function</article-title>. <source>J Leukoc
Biol</source>. <year>2018</year><month>Feb</month>;<volume>103</volume>(<issue>2</issue>):<fpage>295</fpage>–<lpage>309</lpage>.
<pub-id pub-id-type="doi">10.1002/JLB.3MA0517-194RR</pub-id><issn>1938-3673</issn><?supplied-pmid 29345350?><pub-id pub-id-type="pmid">29345350</pub-id></mixed-citation>
              </ref>
              <ref id="R35">
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Brunskole Hummel</surname><given-names>I</given-names></string-name><string-name><surname>Reinartz</surname><given-names>MT</given-names></string-name><string-name><surname>Kälble</surname><given-names>S</given-names></string-name><string-name><surname>Burhenne</surname><given-names>H</given-names></string-name><string-name><surname>Schwede</surname><given-names>F</given-names></string-name><string-name><surname>Buschauer</surname><given-names>A</given-names></string-name><etal>et al.</etal></person-group><article-title>Dissociations in the effects of β2-adrenergic receptor agonists
on cAMP formation and superoxide production in human neutrophils: support
for the concept of functional selectivity</article-title>. <source>PLoS
One</source>. <year>2013</year><month>May</month>;<volume>8</volume>(<issue>5</issue>):<fpage>e64556</fpage>.
<pub-id pub-id-type="doi">10.1371/journal.pone.0064556</pub-id><issn>1932-6203</issn><?supplied-pmid 23741338?><pub-id pub-id-type="pmid">23741338</pub-id></mixed-citation>
              </ref>
              <ref id="R36">
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Cosentino</surname><given-names>M</given-names></string-name><string-name><surname>Marino</surname><given-names>F</given-names></string-name><string-name><surname>Maestroni</surname><given-names>GJ</given-names></string-name></person-group>. <article-title>Sympathoadrenergic modulation of hematopoiesis:
a review of available evidence and of therapeutic
perspectives.</article-title><source>Front Cell Neurosci</source>. <year>2015</year>;<volume>9</volume>:<fpage>302</fpage>.
Published 2015 Aug 5. doi:<pub-id pub-id-type="doi">10.3389/fncel.2015.00302</pub-id><pub-id pub-id-type="pmid">26300737</pub-id></mixed-citation>
              </ref>
              <ref id="R37">
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Maestroni</surname><given-names>GJ</given-names></string-name></person-group>. <article-title>Adrenergic modulation of
hematopoiesis</article-title>. <source>J Neuroimmune Pharmacol</source>.
<year>2020</year><month>Mar</month>;<volume>15</volume>(<issue>1</issue>):<fpage>82</fpage>–<lpage>92</lpage>.
<pub-id pub-id-type="doi">10.1007/s11481-019-09840-7</pub-id><issn>1557-1904</issn><?supplied-pmid 30762159?><pub-id pub-id-type="pmid">30762159</pub-id></mixed-citation>
              </ref>
              <ref id="R38">
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Ho</surname><given-names>YH</given-names></string-name><string-name><surname>Del Toro</surname><given-names>R</given-names></string-name><string-name><surname>Rivera-Torres</surname><given-names>J</given-names></string-name><string-name><surname>Rak</surname><given-names>J</given-names></string-name><string-name><surname>Korn</surname><given-names>C</given-names></string-name><string-name><surname>García-García</surname><given-names>A</given-names></string-name><etal>et al.</etal></person-group><article-title>Remodeling of bone marrow hematopoietic stem cell niches promotes
myeloid cell expansion during premature or physiological
aging</article-title>. <source>Cell Stem Cell</source>. <year>2019</year><month>Sep</month>;<volume>25</volume>(<issue>3</issue>):<fpage>407</fpage>–<lpage>418.e6</lpage>.
<pub-id pub-id-type="doi">10.1016/j.stem.2019.06.007</pub-id><issn>1875-9777</issn><?supplied-pmid 31303548?><pub-id pub-id-type="pmid">31303548</pub-id></mixed-citation>
              </ref>
              <ref id="R39">
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Raaijmakers</surname><given-names>MH</given-names></string-name></person-group>. <article-title>Aging of the hematopoietic stem cell niche: an
unnerving matter</article-title>. <source>Cell Stem Cell</source>.
<year>2019</year><month>Sep</month>;<volume>25</volume>(<issue>3</issue>):<fpage>301</fpage>–<lpage>3</lpage>.
<pub-id pub-id-type="doi">10.1016/j.stem.2019.08.008</pub-id><issn>1875-9777</issn><?supplied-pmid 31491392?><pub-id pub-id-type="pmid">31491392</pub-id></mixed-citation>
              </ref>
              <ref id="R40">
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Carrasco</surname><given-names>GA</given-names></string-name><string-name><surname>Van de Kar</surname><given-names>LD</given-names></string-name></person-group>. <article-title>Neuroendocrine pharmacology of
stress</article-title>. <source>Eur J Pharmacol</source>. <year>2003</year><month>Feb</month>;<volume>463</volume>(<issue>1-3</issue>):<fpage>235</fpage>–<lpage>72</lpage>.
<pub-id pub-id-type="doi">10.1016/s0014-2999(03)01285-8</pub-id>
<pub-id pub-id-type="doi">10.1016/S0014-2999(03)01285-8</pub-id><issn>0014-2999</issn><?supplied-pmid 12600714?><pub-id pub-id-type="pmid">12600714</pub-id></mixed-citation>
              </ref>
              <ref id="R41">
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Shin</surname><given-names>KJ</given-names></string-name><string-name><surname>Lee</surname><given-names>YJ</given-names></string-name><string-name><surname>Yang</surname><given-names>YR</given-names></string-name><string-name><surname>Park</surname><given-names>S</given-names></string-name><string-name><surname>Suh</surname><given-names>PG</given-names></string-name><string-name><surname>Follo</surname><given-names>MY</given-names></string-name><etal>et al.</etal></person-group><article-title>Molecular mechanisms underlying psychological stress and
cancer</article-title>. <source>Curr Pharm Des</source>.
<year>2016</year>;<volume>22</volume>(<issue>16</issue>):<fpage>2389</fpage>–<lpage>402</lpage>.
<pub-id pub-id-type="doi">10.2174/1381612822666160226144025</pub-id><issn>1873-4286</issn><?supplied-pmid 26916018?><pub-id pub-id-type="pmid">26916018</pub-id></mixed-citation>
              </ref>
              <ref id="R42">
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Maryanovich</surname><given-names>M</given-names></string-name><string-name><surname>Zahalka</surname><given-names>AH</given-names></string-name><string-name><surname>Pierce</surname><given-names>H</given-names></string-name><string-name><surname>Pinho</surname><given-names>S</given-names></string-name><string-name><surname>Nakahara</surname><given-names>F</given-names></string-name><string-name><surname>Asada</surname><given-names>N</given-names></string-name><etal>et al.</etal></person-group><article-title>Adrenergic nerve degeneration in bone marrow drives aging of the
hematopoietic stem cell niche</article-title><comment>[published correction appears in Nat Med. 2019
Apr;25(4):701]</comment>. <source>Nat Med</source>. <year>2018</year><month>Jun</month>;<volume>24</volume>(<issue>6</issue>):<fpage>782</fpage>–<lpage>91</lpage>.
<pub-id pub-id-type="doi">10.1038/s41591-018-0030-x</pub-id><issn>1546-170X</issn><?supplied-pmid 29736022?><pub-id pub-id-type="pmid">29736022</pub-id></mixed-citation>
              </ref>
              <ref id="R43">
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Katayama</surname><given-names>Y</given-names></string-name><string-name><surname>Battista</surname><given-names>M</given-names></string-name><string-name><surname>Kao</surname><given-names>WM</given-names></string-name><string-name><surname>Hidalgo</surname><given-names>A</given-names></string-name><string-name><surname>Peired</surname><given-names>AJ</given-names></string-name><string-name><surname>Thomas</surname><given-names>SA</given-names></string-name><etal>et al.</etal></person-group><article-title>Signals from the sympathetic nervous system regulate
hematopoietic stem cell egress from bone marrow</article-title>.
<source>Cell</source>. <year>2006</year><month>Jan</month>;<volume>124</volume>(<issue>2</issue>):<fpage>407</fpage>–<lpage>21</lpage>.
<pub-id pub-id-type="doi">10.1016/j.cell.2005.10.041</pub-id><issn>0092-8674</issn><?supplied-pmid 16439213?><pub-id pub-id-type="pmid">16439213</pub-id></mixed-citation>
              </ref>
              <ref id="R44">
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Méndez-Ferrer</surname><given-names>S</given-names></string-name><string-name><surname>Battista</surname><given-names>M</given-names></string-name><string-name><surname>Frenette</surname><given-names>PS</given-names></string-name></person-group>. <article-title>Cooperation of beta(2)- and beta(3)-adrenergic
receptors in hematopoietic progenitor cell mobilization</article-title>.
<source>Ann N Y Acad Sci</source>. <year>2010</year><month>Mar</month>;<volume>1192</volume>(<issue>1</issue>):<fpage>139</fpage>–<lpage>44</lpage>.
<pub-id pub-id-type="doi">10.1111/j.1749-6632.2010.05390.x</pub-id><issn>1749-6632</issn><?supplied-pmid 20392229?><pub-id pub-id-type="pmid">20392229</pub-id></mixed-citation>
              </ref>
              <ref id="R45">
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Hanoun</surname><given-names>M</given-names></string-name><string-name><surname>Zhang</surname><given-names>D</given-names></string-name><string-name><surname>Mizoguchi</surname><given-names>T</given-names></string-name><string-name><surname>Pinho</surname><given-names>S</given-names></string-name><string-name><surname>Pierce</surname><given-names>H</given-names></string-name><string-name><surname>Kunisaki</surname><given-names>Y</given-names></string-name><etal>et al.</etal></person-group><article-title>Acute myelogenous leukemia-induced sympathetic neuropathy
promotes malignancy in an altered hematopoietic stem cell
niche</article-title>. <source>Cell Stem Cell</source>. <year>2014</year><month>Sep</month>;<volume>15</volume>(<issue>3</issue>):<fpage>365</fpage>–<lpage>75</lpage>.
<pub-id pub-id-type="doi">10.1016/j.stem.2014.06.020</pub-id><issn>1875-9777</issn><?supplied-pmid 25017722?><pub-id pub-id-type="pmid">25017722</pub-id></mixed-citation>
              </ref>
              <ref id="R46">
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Knight</surname><given-names>JM</given-names></string-name><string-name><surname>Syrjala</surname><given-names>KL</given-names></string-name><string-name><surname>Majhail</surname><given-names>NS</given-names></string-name><string-name><surname>Martens</surname><given-names>M</given-names></string-name><string-name><surname>Le-Rademacher</surname><given-names>J</given-names></string-name><string-name><surname>Logan</surname><given-names>BR</given-names></string-name><etal>et al.</etal></person-group><article-title>Patient-Reported Outcomes and Socioeconomic Status as Predictors
of Clinical Outcomes after Hematopoietic Stem Cell Transplantation: A Study
from the Blood and Marrow Transplant Clinical Trials Network 0902
Trial</article-title>. <source>Biol Blood Marrow Transplant</source>.
<year>2016</year><month>Dec</month>;<volume>22</volume>(<issue>12</issue>):<fpage>2256</fpage>–<lpage>63</lpage>.
<pub-id pub-id-type="doi">10.1016/j.bbmt.2016.08.016</pub-id><issn>1523-6536</issn><?supplied-pmid 27565521?><pub-id pub-id-type="pmid">27565521</pub-id></mixed-citation>
              </ref>
              <ref id="R47">
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Knight</surname><given-names>JM</given-names></string-name><string-name><surname>Rizzo</surname><given-names>JD</given-names></string-name><string-name><surname>Logan</surname><given-names>BR</given-names></string-name><string-name><surname>Wang</surname><given-names>T</given-names></string-name><string-name><surname>Arevalo</surname><given-names>JM</given-names></string-name><string-name><surname>Ma</surname><given-names>J</given-names></string-name><etal>et al.</etal></person-group><article-title>Low Socioeconomic Status, Adverse Gene Expression Profiles, and
Clinical Outcomes in Hematopoietic Stem Cell Transplant
Recipients</article-title>. <source>Clin Cancer Res</source>.
<year>2016</year><month>Jan</month>;<volume>22</volume>(<issue>1</issue>):<fpage>69</fpage>–<lpage>78</lpage>.
<pub-id pub-id-type="doi">10.1158/1078-0432.CCR-15-1344</pub-id><issn>1557-3265</issn><?supplied-pmid 26286914?><pub-id pub-id-type="pmid">26286914</pub-id></mixed-citation>
              </ref>
              <ref id="R48">
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Knight</surname><given-names>JM</given-names></string-name><string-name><surname>Kerswill</surname><given-names>SA</given-names></string-name><string-name><surname>Hari</surname><given-names>P</given-names></string-name><string-name><surname>Cole</surname><given-names>SW</given-names></string-name><string-name><surname>Logan</surname><given-names>BR</given-names></string-name><string-name><surname>D’Souza</surname><given-names>A</given-names></string-name><etal>et al.</etal></person-group><article-title>Repurposing existing medications as cancer therapy: design and
feasibility of a randomized pilot investigating propranolol administration
in patients receiving hematopoietic cell transplantation</article-title>.
<source>BMC Cancer</source>. <year>2018</year><month>May</month>;<volume>18</volume>(<issue>1</issue>):<fpage>593</fpage>.
<pub-id pub-id-type="doi">10.1186/s12885-018-4509-0</pub-id><issn>1471-2407</issn><?supplied-pmid 29793446?><pub-id pub-id-type="pmid">29793446</pub-id></mixed-citation>
              </ref>
              <ref id="R49">
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Knight</surname><given-names>JM</given-names></string-name><string-name><surname>Rizzo</surname><given-names>JD</given-names></string-name><string-name><surname>Wang</surname><given-names>T</given-names></string-name><string-name><surname>He</surname><given-names>N</given-names></string-name><string-name><surname>Logan</surname><given-names>BR</given-names></string-name><string-name><surname>Spellman</surname><given-names>SR</given-names></string-name><etal>et al.</etal></person-group><article-title>Molecular Correlates of Socioeconomic Status and Clinical
Outcomes Following Hematopoietic Cell Transplantation for
Leukemia</article-title>. <source>JNCI Cancer Spectr</source>.
<year>2019</year><month>Sep</month>;<volume>3</volume>(<issue>4</issue>):<elocation-id>pkz073</elocation-id>.
<pub-id pub-id-type="doi">10.1093/jncics/pkz073</pub-id><issn>2515-5091</issn><?supplied-pmid 31763620?><pub-id pub-id-type="pmid">31763620</pub-id></mixed-citation>
              </ref>
              <ref id="R50">
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Knight</surname><given-names>JM</given-names></string-name><string-name><surname>Rizzo</surname><given-names>JD</given-names></string-name><string-name><surname>Hari</surname><given-names>P</given-names></string-name><string-name><surname>Pasquini</surname><given-names>MC</given-names></string-name><string-name><surname>Giles</surname><given-names>KE</given-names></string-name><string-name><surname>D’Souza</surname><given-names>A</given-names></string-name><etal>et al.</etal></person-group><article-title>Propranolol inhibits molecular risk markers in HCT recipients: a
phase 2 randomized controlled biomarker trial</article-title>. <source>Blood
Adv</source>. <year>2020</year><month>Feb</month>;<volume>4</volume>(<issue>3</issue>):<fpage>467</fpage>–<lpage>76</lpage>.
<pub-id pub-id-type="doi">10.1182/bloodadvances.2019000765</pub-id><issn>2473-9537</issn><?supplied-pmid 32027744?><pub-id pub-id-type="pmid">32027744</pub-id></mixed-citation>
              </ref>
              <ref id="R51">
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Baker</surname><given-names>KS</given-names></string-name><string-name><surname>Davies</surname><given-names>SM</given-names></string-name><string-name><surname>Majhail</surname><given-names>NS</given-names></string-name><string-name><surname>Hassebroek</surname><given-names>A</given-names></string-name><string-name><surname>Klein</surname><given-names>JP</given-names></string-name><string-name><surname>Ballen</surname><given-names>KK</given-names></string-name><etal>et al.</etal></person-group><article-title>Race and socioeconomic status influence outcomes of unrelated
donor hematopoietic cell transplantation</article-title>. <source>Biol Blood
Marrow Transplant</source>. <year>2009</year><month>Dec</month>;<volume>15</volume>(<issue>12</issue>):<fpage>1543</fpage>–<lpage>54</lpage>.
<pub-id pub-id-type="doi">10.1016/j.bbmt.2009.07.023</pub-id><issn>1523-6536</issn><?supplied-pmid 19896078?><pub-id pub-id-type="pmid">19896078</pub-id></mixed-citation>
              </ref>
              <ref id="R52">
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Silla</surname><given-names>L</given-names></string-name><string-name><surname>Fischer</surname><given-names>GB</given-names></string-name><string-name><surname>Paz</surname><given-names>A</given-names></string-name><string-name><surname>Daudt</surname><given-names>LE</given-names></string-name><string-name><surname>Mitto</surname><given-names>I</given-names></string-name><string-name><surname>Katz</surname><given-names>B</given-names></string-name><etal>et al.</etal></person-group><article-title>Patient socioeconomic status as a prognostic factor for
allo-SCT</article-title>. <source>Bone Marrow Transplant</source>.
<year>2009</year><month>Apr</month>;<volume>43</volume>(<issue>7</issue>):<fpage>571</fpage>–<lpage>7</lpage>.
<pub-id pub-id-type="doi">10.1038/bmt.2008.358</pub-id><issn>1476-5365</issn><?supplied-pmid 18978820?><pub-id pub-id-type="pmid">18978820</pub-id></mixed-citation>
              </ref>
              <ref id="R53">
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Shih</surname><given-names>M</given-names></string-name><string-name><surname>Simon</surname><given-names>PA</given-names></string-name></person-group>. <article-title>Health-related quality of life among adults with
serious psychological distress and chronic medical
conditions.</article-title><source>Qual Life Res</source>.
<year>2008</year>;<volume>17</volume>(<issue>4</issue>):<fpage>521</fpage>-528.<pub-id pub-id-type="pmid">18365766</pub-id></mixed-citation>
              </ref>
              <ref id="R54">
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Wang</surname><given-names>XS</given-names></string-name><string-name><surname>Shi</surname><given-names>Q</given-names></string-name><string-name><surname>Shah</surname><given-names>ND</given-names></string-name><string-name><surname>Heijnen</surname><given-names>CJ</given-names></string-name><string-name><surname>Cohen</surname><given-names>EN</given-names></string-name><string-name><surname>Reuben</surname><given-names>JM</given-names></string-name><etal>et al.</etal></person-group><article-title>Inflammatory markers and development of symptom burden in
patients with multiple myeloma during autologous stem cell
transplantation</article-title>. <source>Clin Cancer Res</source>.
<year>2014</year><month>Mar</month>;<volume>20</volume>(<issue>5</issue>):<fpage>1366</fpage>–<lpage>74</lpage>.
<pub-id pub-id-type="doi">10.1158/1078-0432.CCR-13-2442</pub-id><issn>1557-3265</issn><?supplied-pmid 24423611?><pub-id pub-id-type="pmid">24423611</pub-id></mixed-citation>
              </ref>
              <ref id="R55">
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Wong</surname><given-names>GW</given-names></string-name><string-name><surname>Wright</surname><given-names>JM</given-names></string-name></person-group>. <article-title>Blood pressure lowering efficacy of nonselective
beta-blockers for primary hypertension</article-title>. <source>Cochrane
Database Syst Rev</source>. <year>2014</year><month>Feb</month>;(<issue>2</issue>):<elocation-id>CD007452</elocation-id>.
<pub-id pub-id-type="doi">10.1002/14651858.CD007452.pub2</pub-id><issn>1469-493X</issn><?supplied-pmid 24585007?><pub-id pub-id-type="pmid">24585007</pub-id></mixed-citation>
              </ref>
              <ref id="R56">
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Cole</surname><given-names>SW</given-names></string-name><string-name><surname>Sood</surname><given-names>AK</given-names></string-name></person-group>. <article-title>Molecular pathways: beta-adrenergic signaling in
cancer</article-title>. <source>Clin Cancer Res</source>. <year>2012</year><month>Mar</month>;<volume>18</volume>(<issue>5</issue>):<fpage>1201</fpage>–<lpage>6</lpage>.
<pub-id pub-id-type="doi">10.1158/1078-0432.CCR-11-0641</pub-id><issn>1557-3265</issn><?supplied-pmid 22186256?><pub-id pub-id-type="pmid">22186256</pub-id></mixed-citation>
              </ref>
              <ref id="R57">
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Lin</surname><given-names>X</given-names></string-name><string-name><surname>Luo</surname><given-names>K</given-names></string-name><string-name><surname>Lv</surname><given-names>Z</given-names></string-name><string-name><surname>Huang</surname><given-names>J</given-names></string-name></person-group>. <article-title>Beta-adrenoceptor action on pancreatic cancer
cell proliferation and tumor growth in mice</article-title>.
<source>Hepatogastroenterology</source>. <year>2012</year><month>Mar-Apr</month>;<volume>59</volume>(<issue>114</issue>):<fpage>584</fpage>–<lpage>8</lpage>.
<pub-id pub-id-type="doi">10.5754/hge11271</pub-id><issn>0172-6390</issn><?supplied-pmid 22353526?><pub-id pub-id-type="pmid">22353526</pub-id></mixed-citation>
              </ref>
              <ref id="R58">
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Sloan</surname><given-names>EK</given-names></string-name><string-name><surname>Priceman</surname><given-names>SJ</given-names></string-name><string-name><surname>Cox</surname><given-names>BF</given-names></string-name><string-name><surname>Yu</surname><given-names>S</given-names></string-name><string-name><surname>Pimentel</surname><given-names>MA</given-names></string-name><string-name><surname>Tangkanangnukul</surname><given-names>V</given-names></string-name><etal>et al.</etal></person-group><article-title>The sympathetic nervous system induces a metastatic switch in
primary breast cancer</article-title>. <source>Cancer Res</source>.
<year>2010</year><month>Sep</month>;<volume>70</volume>(<issue>18</issue>):<fpage>7042</fpage>–<lpage>52</lpage>.
<pub-id pub-id-type="doi">10.1158/0008-5472.CAN-10-0522</pub-id><issn>1538-7445</issn><?supplied-pmid 20823155?><pub-id pub-id-type="pmid">20823155</pub-id></mixed-citation>
              </ref>
              <ref id="R59">
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Lamkin</surname><given-names>DM</given-names></string-name><string-name><surname>Sloan</surname><given-names>EK</given-names></string-name><string-name><surname>Patel</surname><given-names>AJ</given-names></string-name><string-name><surname>Chiang</surname><given-names>BS</given-names></string-name><string-name><surname>Pimentel</surname><given-names>MA</given-names></string-name><string-name><surname>Ma</surname><given-names>JC</given-names></string-name><etal>et al.</etal></person-group><article-title>Chronic stress enhances progression of acute lymphoblastic
leukemia via β-adrenergic signaling</article-title>. <source>Brain Behav
Immun</source>. <year>2012</year><month>May</month>;<volume>26</volume>(<issue>4</issue>):<fpage>635</fpage>–<lpage>41</lpage>.
<pub-id pub-id-type="doi">10.1016/j.bbi.2012.01.013</pub-id><issn>1090-2139</issn><?supplied-pmid 22306453?><pub-id pub-id-type="pmid">22306453</pub-id></mixed-citation>
              </ref>
              <ref id="R60">
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Kim-Fuchs</surname><given-names>C</given-names></string-name><string-name><surname>Le</surname><given-names>CP</given-names></string-name><string-name><surname>Pimentel</surname><given-names>MA</given-names></string-name><string-name><surname>Shackleford</surname><given-names>D</given-names></string-name><string-name><surname>Ferrari</surname><given-names>D</given-names></string-name><string-name><surname>Angst</surname><given-names>E</given-names></string-name><etal>et al.</etal></person-group><article-title>Chronic stress accelerates pancreatic cancer growth and invasion:
a critical role for beta-adrenergic signaling in the pancreatic
microenvironment</article-title>. <source>Brain Behav Immun</source>.
<year>2014</year><month>Aug</month>;<volume>40</volume>:<fpage>40</fpage>–<lpage>7</lpage>.
<pub-id pub-id-type="doi">10.1016/j.bbi.2014.02.019</pub-id><issn>1090-2139</issn><?supplied-pmid 24650449?><pub-id pub-id-type="pmid">24650449</pub-id></mixed-citation>
              </ref>
              <ref id="R61">
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Reagan-Shaw</surname><given-names>S</given-names></string-name><string-name><surname>Nihal</surname><given-names>M</given-names></string-name><string-name><surname>Ahmad</surname><given-names>N</given-names></string-name></person-group>. <article-title>Dose translation from animal to human studies
revisited</article-title>. <source>FASEB J</source>. <year>2008</year><month>Mar</month>;<volume>22</volume>(<issue>3</issue>):<fpage>659</fpage>–<lpage>61</lpage>.
<pub-id pub-id-type="doi">10.1096/fj.07-9574LSF</pub-id><issn>1530-6860</issn><?supplied-pmid 17942826?><pub-id pub-id-type="pmid">17942826</pub-id></mixed-citation>
              </ref>
              <ref id="R62">
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Wittchen</surname><given-names>ES</given-names></string-name><string-name><surname>Aghajanian</surname><given-names>A</given-names></string-name><string-name><surname>Burridge</surname><given-names>K</given-names></string-name></person-group>. <article-title>Isoform-specific differences between Rap1A and
Rap1B GTPases in the formation of endothelial cell
junctions</article-title>. <source>Small GTPases</source>. <year>2011</year><month>Mar</month>;<volume>2</volume>(<issue>2</issue>):<fpage>65</fpage>–<lpage>76</lpage>.
<pub-id pub-id-type="doi">10.4161/sgtp.2.2.15735</pub-id><issn>2154-1256</issn><?supplied-pmid 21776404?><pub-id pub-id-type="pmid">21776404</pub-id></mixed-citation>
              </ref>
              <ref id="R63">
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Wittchen</surname><given-names>ES</given-names></string-name><string-name><surname>Nishimura</surname><given-names>E</given-names></string-name><string-name><surname>McCloskey</surname><given-names>M</given-names></string-name><string-name><surname>Wang</surname><given-names>H</given-names></string-name><string-name><surname>Quilliam</surname><given-names>LA</given-names></string-name><string-name><surname>Chrzanowska-Wodnicka</surname><given-names>M</given-names></string-name><etal>et al.</etal></person-group><article-title>Rap1 GTPase activation and barrier enhancement in rpe inhibits
choroidal neovascularization in vivo</article-title>. <source>PLoS
One</source>. <year>2013</year><month>Sep</month>;<volume>8</volume>(<issue>9</issue>):<fpage>e73070</fpage>.
<pub-id pub-id-type="doi">10.1371/journal.pone.0073070</pub-id><issn>1932-6203</issn><?supplied-pmid 24039860?><pub-id pub-id-type="pmid">24039860</pub-id></mixed-citation>
              </ref>
              <ref id="R64">
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Hwa</surname><given-names>YL</given-names></string-name><string-name><surname>Shi</surname><given-names>Q</given-names></string-name><string-name><surname>Kumar</surname><given-names>SK</given-names></string-name><string-name><surname>Lacy</surname><given-names>MQ</given-names></string-name><string-name><surname>Gertz</surname><given-names>MA</given-names></string-name><string-name><surname>Kapoor</surname><given-names>P</given-names></string-name><etal>et al.</etal></person-group><article-title>Beta-blockers improve survival outcomes in patients with multiple
myeloma: a retrospective evaluation</article-title>. <source>Am J
Hematol</source>. <year>2017</year><month>Jan</month>;<volume>92</volume>(<issue>1</issue>):<fpage>50</fpage>–<lpage>5</lpage>.
<pub-id pub-id-type="doi">10.1002/ajh.24582</pub-id><issn>1096-8652</issn><?supplied-pmid 27733010?><pub-id pub-id-type="pmid">27733010</pub-id></mixed-citation>
              </ref>
              <ref id="R65">
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Cheng</surname><given-names>Y</given-names></string-name><string-name><surname>Sun</surname><given-names>F</given-names></string-name><string-name><surname>D’Souza</surname><given-names>A</given-names></string-name><string-name><surname>Dhakal</surname><given-names>B</given-names></string-name><string-name><surname>Pisano</surname><given-names>M</given-names></string-name><string-name><surname>Chhabra</surname><given-names>S</given-names></string-name><etal>et al.</etal></person-group><article-title>Autonomic nervous system control of multiple
myeloma</article-title>. <source>Blood Rev</source>. <year>2020</year><month>Aug</month>;<volume>100741</volume>: <pub-id pub-id-type="doi">10.1016/j.blre.2020.100741</pub-id><issn>0268-960X</issn><?supplied-pmid 32807576?><pub-id pub-id-type="pmid">32807576</pub-id></mixed-citation>
              </ref>
            </ref-list>
          </back>
          <floats-group>
            <fig position="float" id="F1">
              <label>Figure 1</label>
              <caption>
                <p><bold>Specificity of commercial antibodies for Rap1A and Rap1B</bold>. HEK293T
cells were transfected with the indicated cDNAs expressing wildtype or mutant
forms of Rap1A or Rap1B. Control cells were transfected with the cDNA vector.
The cells were treated with 15 mM mevastatin (Mev, lanes 2, 6, and 10) to
inhibit prenylation, or they were untreated (lanes 1, 3-5, and 7-9). Cell
lysates were immunoblotted with the indicated commercial antibodies to Rap1. All
immunoblots are shown at the same exposure. Results are representative of at
least three independent experiments conducted for each antibody.</p>
              </caption>
              <graphic xlink:href="yjbm_95_1_45_g01" position="float"/>
            </fig>
            <fig position="float" id="F2">
              <label>Figure 2</label>
              <caption>
                <p><bold>Antibodies that selectively react with either Rap1A or Rap1B exhibit
similar abilities to detect the prenylated and non-prenylated forms of the
small GTPases</bold>. HEK293T cells were treated with 15 mM mevastatin for
18 hours (even numbered lanes) or left untreated (odd numbered lanes). Cell
lysates were immunoblotted using the Rap1A-selective antibody (Santa Cruz,
sc-3987455; top panel) or the Rap1B-selective antibody (Cell Signaling, 2326;
bottom panel). The prenylated and non-prenylated forms of the small GTPases were
detected by their differences in migration. Both immunoblots are shown at the
same exposure. Results are representative of at least three independent
experiments conducted for each antibody.</p>
              </caption>
              <graphic xlink:href="yjbm_95_1_45_g02" position="float"/>
            </fig>
            <fig position="float" id="F3">
              <label>Figure 3</label>
              <caption>
                <p><bold>Expression of Rap1A and Rap1B in PMNC differs between different patients
and different collection times</bold>. Blood samples were collected from
patients at baseline at 7 ± 2 days before HCT (B), 2 days before HCT (-2), and
28 days after HCT (+28). Asterisks indicate the patients who received
propranolol, which was started immediately after the first blood draw at the
baseline collection period. PMNC were isolated from the blood samples, and 20 mg
of protein from each PMNC lysate was immunoblotted using the Rap1A-specific
antibody (Santa Cruz, sc-3987455; top panel) or the Rap1B-specific antibody
(Cell Signaling, 2326; bottom panel). The prenylated and non-prenylated forms of
the small GTPases were detected by their differences in migration. Results are
representative of at least three independent experiments conducted for each
antibody.</p>
              </caption>
              <graphic xlink:href="yjbm_95_1_45_g03" position="float"/>
            </fig>
            <fig position="float" id="F4">
              <label>Figure 4</label>
              <caption>
                <p><bold>Log-transformed Rap1A (A) and Rap1B (B) values in both control and
propranolol treatment groups throughout the study time-course: Baseline
(BL), Pre-HCT (Pre), and Post-HCT (Post)</bold>. Relative to the control
group, propranolol-treated patients did not show significantly altered levels of
prenylated Rap1A (F=0.20, p=0.82) (A), prenylated Rap1B (F=0.90, p=0.41) (B), or
total levels of Rap1A or Rap1B at any time points.</p>
              </caption>
              <graphic xlink:href="yjbm_95_1_45_g04" position="float"/>
            </fig>
            <fig position="float" id="F5">
              <label>Figure 5</label>
              <caption>
                <p><bold>Correlation between log-transformed Rap1A (A) or log-transformed Rap1B (B)
and days to platelet engraftment</bold>. There was a strong correlation
between higher Rap1B (B) expression at baseline in all participants and more
days required for platelet engraftment (HR=0.41, 95% CI: 0.19, 0.86;
p=0.019). There was no significant correlation between baseline
Rap1A (A) expression and the days required for platelet engraftment for all
participants (HR=0.55, 95% CI: 0.27, 1.10, p=0.091).</p>
              </caption>
              <graphic xlink:href="yjbm_95_1_45_g05" position="float"/>
            </fig>
          </floats-group>
        </article>
      </metadata>
    </record>
  </GetRecord>
</OAI-PMH>
